-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GDLUJGAZD6hOYaDYR9GNQsEGfhynuxhQJkwdKIVZ2S3yf8Rok3+hvIwT6z3ACeui
 UO4S+vhLXmrgM75XF0Jh5g==

<SEC-DOCUMENT>0001144204-07-027238.txt : 20070518
<SEC-HEADER>0001144204-07-027238.hdr.sgml : 20070518
<ACCEPTANCE-DATETIME>20070518151611
ACCESSION NUMBER:		0001144204-07-027238
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20070518
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070518
DATE AS OF CHANGE:		20070518

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TARGETED GENETICS CORP /WA/
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23930
		FILM NUMBER:		07864533

	BUSINESS ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		2066237612

	MAIL ADDRESS:	
		STREET 1:		1100 OLIVE WAY
		STREET 2:		STE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v076014_8k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><a name="fis_form">&#160;</a></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>WASHINGTON,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>___________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>FORM
      8-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CURRENT
      REPORT</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      To Section 13 or 15(d) of the Securities Exchange Act of
      1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="50%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date
                of Report (Date of earliest event reported) </font></div>
            </td>
            <td valign="top" width="50%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>May
                18, 2007</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="100%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Targeted
                Genetics Corporation</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="100%">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Exact
                name of registrant as specified in its
                charter)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington</strong></font></div>
            </td>
            <td valign="top" width="34%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>0-23930</strong></font></div>
            </td>
            <td valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>91-1549568</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(State
                or other jurisdiction </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of
                incorporation)</font></div>
            </td>
            <td valign="top" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Commission
                File </font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number)</font></div>
            </td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(IRS
                Employer</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Identification
                No.)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="67%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>1100
                Olive Way, Suite 100, Seattle, Washington</strong></font></div>
            </td>
            <td valign="top" width="33%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>98101</strong></font></div>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" width="67%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
                of principal executive offices)</font></div>
            </td>
            <td valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Zip
                Code)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="50%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant's
                telephone number, including area code</font></div>
            </td>
            <td valign="top" width="50%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(206)
                623-7612</strong></font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td valign="top" width="100%" style="border-bottom: black thin solid;">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Not
                Applicable</strong></font></div>
            </td>
          </tr>
          <tr>
            <td valign="top" width="100%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Former
                name or former address if changed since last
                report)</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 99pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Check
      the
      appropriate box below if the Form 8-K filing is intended to simultaneously
      satisfy the filing obligation of the registrant under any of the following
      provisions (see General Instruction A.2. below):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#168;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 27.9pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item&#160;8.01.
      Other Events. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On
      May
      17, 2007, Targeted Genetics Corporation, in collaboration with Celladon
      Corporation, announced the initiation of a Phase I clinical trial of
      MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      (AAV1/SERCA2a) in patients with cardiomyopathy and symptoms of heart failure.
      A
      copy of the press release announcing this achievement and describing the Phase
      I
      trial is attached as Exhibit 99.1 to this current report and is incorporated
      herein by reference.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Item&#160;9.01.
      Financial Statements and Exhibits. </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;Exhibits.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
      Press Release of Targeted Genetics Corporation dated May 17, 2007. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Targeted
                Genetics Corporation </font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td>&#160;</td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;David
              J.
              Poston</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="1" width="70%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">David
                  J. Poston&#160; </font></div>
              </div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Vice
                President and</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief
                Financial Officer&#160; </font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "></font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated:
      May 18, 2007 </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>INDEX
      TO EXHIBITS </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div align="left">
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="10%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Exhibit
                  </strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Number
                  </u></strong></font></div>
              </td>
              <td align="left" valign="top" width="2%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="88%" style="border-bottom: medium none;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>Description</u></strong></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="10%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div>
              </td>
              <td align="left" valign="top" width="2%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
              <td align="left" valign="top" width="88%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Press
                  Release of Targeted Genetics Corporation dated May 17, 2007
                  </font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v076014_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit
      99.1</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div align="center">
        <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="white">
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<IMG SRC="logo1.jpg">
</div>
              </td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<IMG SRC="logo2.jpg">
</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Investor
          and Media Contacts:</strong></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
        <div>
          <table cellpadding="0" cellspacing="0" width="100%">

              <tr>
                <td align="left" valign="top" width="40%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Marion
                    Ferguson</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Celladon
                    Corporation</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(858)
                    366-4288</strong></font></div>
                </td>
                <td align="left" valign="top" width="40%">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Stacie
                    D. Byars</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Targeted
                    Genetics Corporation</font></div>
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(206)
                    521-7392</strong></font></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>CELLADON
        AND TARGETED GENETICS INITIATE PHASE I CLINICAL TRIAL OF
        MYDICAR</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol"><strong>&#212;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
        IN PATIENTS WITH HEART FAILURE</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>La
        Jolla, CA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>and</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Seattle,
        WA</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        - May
        17, 2007 - Celladon Corporation and Targeted Genetics Corporation (Nasdaq:
        TGEN)
        today announced the initiation of a Phase I clinical trial of
        MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (AAV1/SERCA2a) in patients with cardiomyopathy and symptoms of heart failure.
        MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        utilizes
        an adeno-associated virus (AAV) vector to deliver the SERCA2a gene to heart
        muscle tissue. </font></div>
      <div>&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        trial, titled &#8220;Calcium Up-Regulation by Percutaneous Administration of Gene
        Therapy In Cardiac Disease (CUPID Trial),&#8221; is a Phase I/II, two-stage,
        dose-escalation trial designed to evaluate the safety and feasibility of
        a
        single coronary artery infusion of four dose levels of an AAV1 vector expressing
        the transgene for SERCA2a to subjects with ischemic or non-ischemic
        cardiomyopathy and NYHA Class III/IV symptoms of heart failure. In Stage
        1 of
        the trial, 12 subjects will be enrolled and treated with one of four escalating
        doses of open-label MYDICAR&#8482;. In Stage 2 of the trial, 33 subjects will be
        randomized to receive either MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        or
        placebo. Initiation of this trial follows recent approvals by both the National
        Institutes of Health Recombinant DNA Advisory Committee (RAC) without
        requirement of an in-depth public review, and Office of Cellular, Tissue
        and
        Gene Therapies, Center for Biologics Evaluation and Research (CBER) branch
        of
        the Food and Drug Administration. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Celladon's
        therapeutic candidate targets the SERCA2a pathway, an important regulator
        of
        myocardial contractility. Malfunction in this pathway is associated with
        progressive heart failure," said Krisztina Zsebo, Ph.D., chief executive
        officer
        of Celladon Corporation. &#8220;By bringing the levels of this enzyme back to normal
        in the heart, we hope to both demonstrate the safety of MYDICAR&#8482; and provide
        evidence that MYDICAR&#8482; has the potential to halt or reverse the progression of
        disease in heart failure patients.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Targeted
        Genetics and Celladon have a collaboration agreement to develop
        MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for the
        treatment of congestive heart failure. The collaboration combines Targeted
        Genetics&#8217; expertise in the development, manufacture and clinical evaluation of
        AAV-based therapies with Celladon&#8217;s portfolio of genes with potential in the
        treatment of congestive heart failure. &#8220;The initiation of this trial highlights
        the enormous potential of our AAV delivery platform to enable novel treatments
        for serious diseases,&#8221; said H. Stewart Parker, president and chief executive
        officer of Targeted Genetics. &#8220;It is our hope that Targeted Genetics&#8217; gene
        delivery technology is proven to be the key that unlocks the potential of
        this
        pathway in treating a disease that affects millions of Americans.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        MYDICAR</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        utilizes
        an AAV1 vector to deliver the SERCA2a gene to the heart using standard cardiac
        catheterization laboratory procedures and equipment. SERCA2a activity is
        decreased in heart tissue obtained from heart failure patients.&#160; To date,
        there have been compelling preclinical results suggesting that gene therapy
        targeting calcium cycling within the heart may improve myocardial contractility
        and reverse the progression of heart failure. Studies in large-animal models
        of
        heart failure demonstrated that administration of MYDICAR</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Symbol">&#212;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        led to
        significant improvements in heart function without any significant safety
        concerns. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        Heart Failure</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Heart
        failure is a serious condition in which the heart progressively loses its
        ability to pump blood efficiently throughout the body. According to the National
        Heart, Lung and Blood Institute, about 5 million people in the United States
        alone have heart failure, and another 550,000 new cases are diagnosed each
        year.
        Heart failure contributes to or causes about 300,000 deaths annually. The
        disease is most common in people age 65 or older, women and African Americans.
        The most common symptoms of heart failure are shortness of breath, feeling
        tired, and swelling in the ankles, feet, legs, and sometimes the abdomen.
        There
        is no cure for heart failure. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        Celladon</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Celladon
        Corporation is a molecular cardiology company based in La Jolla, </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">California
        and founded by Roger J. Hajjar, M.D and Kenneth R. Chien M.D., </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ph.D.
        Founding investors in Celladon include Enterprise Partners Venture Capital
        and
</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Venrock
        Associates, recently joined by Johnson &amp; Johnson Development Corporation. To
        learn more about Celladon, visit Celladon&#8217;s website at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.celladon.net</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        Targeted Genetics</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Targeted
        Genetics Corporation is a biotechnology company committed to the development
        of
        innovative targeted molecular therapies for the prevention and treatment
        of
        acquired and inherited diseases with significant unmet medical need. Targeted
        Genetics&#8217; proprietary Adeno-Associated Virus (AAV) technology platform allows it
        to deliver genes that encode proteins to increase gene function or RNAi to
        decrease or silence gene function. Targeted Genetics&#8217; product development
        efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart
        failure and Huntington's disease. To learn more about Targeted Genetics,
        visit
        Targeted Genetics&#8217; website at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">www.targetedgenetics.com</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em>Safe
        Harbor Statement under the Private Securities Litigation Reform Act of
        1995:</em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>This
        release contains forward-looking statements regarding the initiation and
        purpose
        of a clinical trial of Mydicar, the potential therapeutic benefit of Mydicar,
        the potential of Targeted Genetics&#8217; gene delivery technology and other
        statements about the plans, objectives, intentions and expectations of Targeted
        Genetics. These forward-looking statements involve current expectations,
        forecasts of future events and other statements that are not historical facts.
        Inaccurate assumptions and known and unknown risks and uncertainties can
        affect
        the accuracy of these forward-looking statements. Actual results or developments
        may be materially different from the results projected or implied in these
        forward-looking statements. Factors that could affect our actual results
        include, but are not limited to, the risk of adverse clinical results as
        Mydicar
        moves into and advances in clinical trials, Targeted Genetics&#8217; ability to
        obtain, maintain and protect its intellectual property, Celladon&#8217;s ability to
        recruit and enroll suitable trial participants, Targeted Genetics&#8217; dependence on
        the efforts of third parties, the timing, nature and results of research
        and
        clinical trials, potential development of alternative technologies or more
        effective processes by competitors, and, whether regulatory or institutional
        approvals can be obtained and maintained, as well as other risk factors
        described in Item 1A. Risk Factors in Targeted Genetics&#8217; report on Form 10-K for
        the year ended December 31, 2006 as updated in its Form 10-Q for the quarter
        ended March 31, 2007. You should not rely unduly on these forward-looking
        statements, which apply only as of the date of this release. Targeted Genetics
        undertakes no duty to publicly announce or report revisions to these statements
        as new information becomes available that may change these
        expectations.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">#
        #
        #</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0KV17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-SHP-3HQ
M."`P,#HQ-#HP,P```````Z`!``,````!``$``*`"``0````!````HZ`#``0`
M```!````%0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```G`````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%0"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`Z[*S,[J74OLM%CJJ][JZVL<6B&D[[K-I
M9ZGT-^Q:=UN/TFMM-#3;>\27V.+G0--]CS[OI?1K;[/ZBR>EO;5USWZ39:S7
MLXEVG^<-BN]:K>W,%A^A8P!I\VEVYO\`TMRPQFR#E\W,`\6;W.#B.OLP_JQ_
M1_<;W.^C@Q1'#CX0:'Z1\6577<AKYO8QU??8""/Y7N<_=_56TUS7M#VF6N$@
M^17)DP%TV#4^K#IK?])K0"IOA7-9LLIPR$SC$"0D?T3^[_A-(N)UKK?6?VU1
MT#H-6.<Q])RLC(RRXU5TAWHZ5TEEEEK[#_K].MO0_P`8'_<OI?\`VQ?_`.EU
M7I!;_C,OG3?TH%OF!<QI_P"DNK6U(B(B`!J`=1W8Q9O4[D/,8O6?K'@_6#"Z
M/UUN)=7U1MIQ,C$#V%KZ&>O<V^J]]GMV?0]-=%?DXV.`[(M92TZ`V.#0?\Y5
M\OJV%AYV%@7N<,CJ)>W&`:2":F^I9N</H>TKA,&K+S>J=:RW?5RGZQ/'4;\?
M[5DW4M]-E#O3IQ*Z,MENQM5?N]2O^<]1$1X]:$:']WBU_K*,J\=?/_HOH=&3
MC9`)Q[67!NA-;@X`_P!E9E?5\I_ULNZ,6U_9:L%F4UT'U-[K'4EI?OV>GM9_
MHERF9TOJYLQLKI_U5IZ)EXMU;V9N-E8S(:7-%U5U5+:&Y%=U6ZK98MVC_P#*
M+E?^FFK_`,_V)<`%Z@Z'J#7^*KBO[1TIN_5KJ^7U5G4790K:</.OQ*O3:6S7
M5MV.LWOLW6>[W+0LZCT^MYKLRJ6/:8+'6-!!_JERXO#R,3&^J_UIMS'7LQOV
MEEML.*0+H>ZJJ*76>S<[?M]R6-TRZG'JJ9]0L5[6-#0^V_#>\@#Z5KWU.>^S
M]_<B<8L]!=;QC_TD">@O\C+_`*+WC7->T.80YIU#@9!0;LW#QW!M]]=3CJ`]
M[6G_`*17$=%NNZ;F?6<8N&[I'HX-66.GRQU561Z5Y?;1Z+GX[Z[/3K]U>SU/
M\+57Z?I,T_JI]5_J];]7>GY65T_'R\K,HKR<C(R:V7VOLN:VZUSKKVO?]-R:
M8".I.FFW]8<2X2O0.CF];NJZ]T7`Q35;B=3;E.MLU<[]78RROT+&/]/Z;_TF
MYEBUKLBBAN^^QE3/WGN#1][ER.7T;I?2_KQT!_3L:O$&4S-]:ND!E9-=+!6]
MM+(J8_\`2NWO8W])^>I?5_I73>M]1ZWU'K&-5GY-74+L*D9+&VMJHHV"FNFJ
MT.95])S_`&M]Z)A&@>G#9[_/**!(V1XZ?XKU5&7B9!(Q[J[BWZ0K<'1\=I1=
MS9B1,3'>`N1^N/U=Z%A?5W,ZA@8-&#FX+/M&-DXM;:+&6,,L<+*&L=_8<A=7
MPL?J_P!:NA49[393?@W/OK!+19'I6"JW86N=1ZI]7TOH/]-`0!U!-:]/W?4D
MR(-4]8SJ&`^P5,R:76$P&"QI<3X;=RL+%R_J;]5<C&LH=TG$K#VD;ZJ*ZWC^
M57;6QKV.0_J)DWY7U1Z9=>\V6>D6%QY(8Y]3)_L,:FF(X>($Z&M?%-FZ/:W_
MT.MZRWIISW^B^QETCU?38'L-G\C])4]M_P!'?Z?_`)_]1;58<,*.J.8]L"7/
M:&'R:]@?;7ZO\JIZ^8TEFX>'W.8KV^+KP>Y[/Z7^Z>/]3_X6W>8XO9Q7Q<-:
M>[[?%T_F^'];P_WWZ8POV+ZP^SQZOYN_=/\`UOU_^^+27RJDK')?S7^1W_\`
M`O\`-?\`HS2?>OKM^P_M^!ZGV_\`;D.^R?LB/M7I0[U=WJ?HOLW[^[_SWZRS
MHZO^]]:?\W"_\FO%DEH"^&-7MUX?^;Q,9W/ROM_0OV;_`,Z,3]IGK1ZKLM_9
MQZL&"F=OZS]D^QS7ZGV?^=W_`*+_`*]Z"65]B_YQ9W_-\]7&3N'[0_9@QSB>
MO^?ZG[1+:?MG^F]/_P`^^NO$$D3=_I?+_5X=_P#H*_Q=WVS,^S?:L/\`YTGK
M1P_7;L^V#$&%ZO\`VG^U_LDN?_.?0]3]'O\`YQ=!5^SO^>V1M^T?M']G5[YV
M?9_1]5VS;_VH^T>KO_X+TU\YI)INNNQ[<*>O3</NH_YL_P#-GZR?:?M?[.^V
M9/V[U/3]3UIKW?8OL_M]/UO2^S?:/S_Y_P#1*%`Z]]F;Z;OK'Z4#;ZC>F>I'
M;=ZS_M&_^LO#4D3?CO\`I</;_I('TVZ/O/U3_9G[7ZMO_:7V[TJOVA^UO1^A
M-OI;?L_MV;-__=?T?H+/Z.`:'?\`-@]?'2M[_L^P89Q]N[_M%^UW-RO0W_O_
M`/I1>+))&_5\WZ/S</#M_+@4.FW5]OZ9^S/^=G3_`+9^V/V[^GV?;_1V>EZ/
M_`?JWV7^>]#]G?I/M/J?;?\``HN;]B_YR9O[!/5AG0W]I'IHQSB^K`V_:/VI
M&-]K]+9O]#_S[ZZ\+22-_P!;Y>O#6_\`T%#_``=_Y?X3[9U$5@5?\Z3UP],]
M1OJ_:!AC$Y_1_;_V077^CZNSZ?Z/U%OY?[,_YW=+W>O]M^RW_9O3]/[/Z7L]
M7U9_3[_YOTO2]B^=$D-:&^TMJX?Y?OIZ].C]4N^B?@>%B_4K]G_\V,']F^O]
MBVO]'[5L]:/4LGU?L_Z'Z7T=GYB^<$DP?*=]Q_=_27=1Y?5__]G_[0^F4&AO
M=&]S:&]P(#,N,``X0DE-!"4``````!``````````````````````.$))30/M
M```````0`$@````!``$`2`````$``3A"24T$)@``````#@`````````````_
M@```.$))300-```````$````>#A"24T$&0``````!````!XX0DE-`_,`````
M``D```````````$`.$))300*```````!```X0DE-)Q````````H``0``````
M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&
M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$))
M30/X``````!P``#_____________________________`^@`````________
M_____________________P/H`````/____________________________\#
MZ`````#_____________________________`^@``#A"24T$`````````@`!
M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X
M0DE-!!X```````0`````.$))300:``````,_````!@``````````````%0``
M`*,````%`&P`;P!G`&\`,0````$``````````````````````````0``````
M````````HP```!4``````````````````````0``````````````````````
M```0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````````
M4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"
M=&]M;&]N9P```!4`````4F=H=&QO;F<```"C````!G-L:6-E<U9L3',````!
M3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````
M!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I
M;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`
M````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O
M<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````5````
M`%)G:'1L;VYG````HP````-U<FQ415A4`````0```````&YU;&Q415A4````
M`0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.
M8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````)
M:&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=```
M``EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT
M````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.
M;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG````
M``````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<`
M`````#A"24T$*```````#`````$_\````````#A"24T$%```````!`````(X
M0DE-!`P`````"=P````!````H````!4```'@```G8```"<``&``!_]C_X``0
M2D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_
MVP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4
M$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`!4`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#
M``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!
M`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R
M@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#
M!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3
M%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`.NR
MLS.ZEU+[+18ZJO>ZNMK'%HAI.^ZS:6>I]#?L6G=;C])K;30TVWO$E]CBYT#3
M?8\^[Z7T:V^S^HLGI;VU=<]^DV6LU[.)=I_G#8KO6JWMS!8?H6,`:?-I=N;_
M`-+<L,9L@Y?-S`/%F]S@XCK[,/ZL?T?W&]SOHX,41PX^$&A^D?%E5UW(:^;V
M,=7WV`@C^5[G/W?U5M-<U[0]IEKA(/D5R9,!=-@U/JPZ:W_2:T`J;X5S6;+*
M<,A,XQ`D)']$_N_X32+B=:ZWUG]M4=`Z#5CG,?2<K(R,LN-5=(=Z.E=)999:
M^P_Z_3K;T/\`&!_W+Z7_`-L7_P#I=5Z06_XS+YTW]*!;Y@7,:?\`I+JUM2(B
M(@`:@'4=V,6;U.Y#S&+UGZQX/U@PNC]=;B75]4;:<3(Q`]A:^AGKW-OJO?9[
M=GT/3717Y.-C@.R+64M.@-C@T'_.5?+ZMA8>=A8%[G#(ZB7MQ@&D@FIOJ6;G
M#Z'M*X3!JR\WJG6LMWU<I^L3QU&_'^U9-U+?390[TZ<2NC+9;L;57[O4K_G/
M41$>/6A&A_=XM?ZRC*O'7S_Z+Z'1DXV0"<>UEP;H36X.`/\`9697U?*?];+N
MC%M?V6K!9E-=!]3>ZQU):7[]GI[6?Z)<IF=+ZN;,;*Z?]5:>B9>+=6]F;C96
M,R&ES1=5=52VAN17=5NJV6+=H_\`RBY7_IIJ_P#/]B7`!>H.AZ@U_BJXK^T=
M*;OU:ZOE]59U%V4*VG#SK\2KTVELUU;=CK-[[-UGN]RT+.H]/K>:[,JECVF"
MQUC00?ZI<N+P\C$QOJO]:;<QU[,;]I9;;#BD"Z'NJJBEUGLW.W[?<EC=,NIQ
MZJF?4+%>UC0T/MOPWO(`^E:]]3GOL_?W(G&+/076\8_])`GH+_(R_P"B]XUS
M7M#F$.:=0X&04&[-P\=P;??74XZ@/>UI_P"D5Q'1;KNFYGUG&+ANZ1Z.#5EC
MI\L=55D>E>7VT>BY^.^NSTZ_=7L]3_"U5^GZ3-/ZJ?5?ZO6_5WI^5E=/Q\O*
MS**\G(R,FME]K[+FMNM<ZZ]KW_3<FF`CJ3IIM_6'$N$KT#HYO6[JNO=%P,4U
M6XG4VY3K;-7._5V,LK]"QC_3^F_])N98M:[(HH;OOL94S]Y[@T?>Y<CE]&Z7
MTOZ\=`?T[&KQ!E,S?6KI`96372P5O;2R*F/_`$KM[V-_2?GJ7U?Z5TWK?4>M
M]1ZQC59^35U"["I&2QMK:J*-@IKIJM#F5?2<_P!K?>B81H'IPV>_SRB@2-D>
M.G^*]51EXF02,>ZNXM^D*W!T?':47<V8D3$QW@+D?KC]7>A87U=S.H8&#1@Y
MN"S[1C9.+6VBQEC#+'"RAK'?V'(75\+'ZO\`6KH5&>TV4WX-S[ZP2T61Z5@J
MMV%KG4>J?5]+Z#_30$`=036O3]WU),B#5/6,ZA@/L%3,FEUA,!@L:7$^&W<K
M"Q<OZF_57(QK*'=)Q*P]I&^JBNMX_E5VUL:]CD/ZB9-^5]4>F77O-EGI%A<>
M2&.?4R?[#&IIB.'B!.AK7Q39NCVM_]#K>LMZ:<]_HOL9=(]7TV![#9_(_25/
M;?\`1W^G_P"?_46U6'#"CJCF/;`ESVAA\FO8'VU^K_*J>OF-)9N'A]SF*]OB
MZ\'N>S^E_NGC_4_^%MWF.+V<5\7#6GN^WQ=/YOA_6\/]]^F,+]B^L/L\>K^;
MOW3_`-;]?_OBTE\JI*QR7\U_D=__``+_`#7_`*,TGWKZ[?L/[?@>I]O_`&Y#
MOLG[(C[5Z4.]7=ZGZ+[-^_N_\]^LLZ.K_O?6G_-PO_)KQ9):`OAC5[=>'_F\
M3&=S\K[?T+]F_P#.C$_:9ZT>J[+?V<>K!@IG;^L_9/L<U^I]G_G=_P"B_P"O
M>@EE?8O^<6=_S?/5QD[A^T/V8,<XGK_G^I^T2VG[9_IO3_\`/OKKQ!)$W?Z7
MR_U>'?\`Z"O\7=]LS/LWVK#_`.=)ZT</UV[/M@Q!A>K_`-I_M?[)+G_SGT/4
M_1[_`.<705?L[_GMD;?M'[1_9U>^=GV?T?5=LV_]J/M'J[_^"]-?.:2:;KKL
M>W"GKTW#[J/^;/\`S9^LGVG[7^SOMF3]N]3T_4]::]WV+[/[?3];TOLWVC\_
M^?\`T2A0.O?9F^F[ZQ^E`V^HWIGJ1VW>L_[1O_K+PU)$WX[_`*7#V_Z2!]-N
MC[S]4_V9^U^K;_VE]N]*K]H?M;T?H3;Z6W[/[=FS?_W7]'Z"S^C@&AW_`#8/
M7QTK>_[/L&&<?;N_[1?M=S<KT-_[_P#Z47BR21OU?-^C\W#P[?RX%#IMU?;^
MF?LS_G9T_P"V?MC]N_I]GV_T=GI>C_P'ZM]E_GO0_9WZ3[3ZGVW_``*+F_8O
M^<F;^P3U89T-_:1Z:,<XOJP-OVC]J1C?:_2V;_0_\^^NO"TDC?\`6^7KPUO_
M`-!0_P`'?^7^$^V=1%8%7_.D]</3/4;ZOV@88Q.?T?V_]D%U_H^KL^G^C]1;
M^7^S/^=W2]WK_;?LM_V;T_3^S^E[/5]6?T^_^;]+TO8OG1)#6AOM+:N'^7[Z
M>O3H_5+OHGX'A8OU*_9__-C!_9OK_8MK_1^U;/6CU+)]7[/^A^E]'9^8OG!)
M,'RG?<?W?TEW4>7U?__9.$))300A``````!3`````0$````/`$$`9`!O`&(`
M90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`;P!T
M`&\`<P!H`&\`<``@`$,`4P````$`.$))300&```````'``@````!`0#_X1?Y
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X]
M)^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX;7!M
M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@=&]O
M;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN<SIR
M9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G/@H*
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C(R-V8V8V%B+3`T
M9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8B<*("!X;6QN<SIE>&EF/2=H='1P
M.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3<&%C
M93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q81&EM96YS:6]N
M/C$V,SPO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z4&EX96Q91&EM
M96YS:6]N/C(Q/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(#PO<F1F.D1E<V-R
M:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C(R
M-V8V8V%B+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8B<*("!X;6QN<SIP
M9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\G/@H@/"]R9&8Z1&5S
M8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z
M,C(W9C9C86(M,#1F-BTQ,61C+6(S.38M.68Q.3%C9C,Q8C=B)PH@('AM;&YS
M.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP
M+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO=&]S:&]P.DAI<W1O<GD^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#HR,C=F-F-A8BTP-&8V+3$Q9&,M8C,Y-BTY9C$Y,6-F,S%B
M-V(G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N
M,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^
M"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF9CI84F5S;VQU=&EO;CX*
M("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F.EE297-O;'5T:6]N/@H@
M(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^
M"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TG=75I9#HR,C=F-F-A8BTP-&8V+3$Q9&,M8C,Y-BTY9C$Y,6-F,S%B
M-V(G"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O
M)SX*("`\>&%P.D-R96%T941A=&4^,C`P-RTP-2TQ.%0P,#HQ-#HP,RTP-3HP
M,#PO>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I9GE$871E/C(P,#<M,#4M
M,3A4,#`Z,30Z,#,M,#4Z,#`\+WAA<#I-;V1I9GE$871E/@H@(#QX87`Z365T
M861A=&%$871E/C(P,#<M,#4M,3A4,#`Z,30Z,#,M,#4Z,#`\+WAA<#I-971A
M9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W`@
M0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@/"]R9&8Z1&5S8W)I<'1I
M;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U:60Z,C(W9C9C
M86(M,#1F-BTQ,61C+6(S.38M.68Q.3%C9C,Q8C=B)PH@('AM;&YS.GAA<$U-
M/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ
M1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z,C(W9C9C86$M,#1F
M-BTQ,61C+6(S.38M.68Q.3%C9C,Q8C=B/"]X87!-33I$;V-U;65N=$E$/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z,C(W9C9C86(M,#1F-BTQ,61C+6(S.38M.68Q.3%C9C,Q8C=B
M)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M870^"B`\+W)D
M9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H\/WAP
M86-K970@96YD/2=W)S\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```
M;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`
M`````````````````/;6``$`````TRU(4"`@````````````````````````
M```````````````````````````````````````18W!R=````5`````S9&5S
M8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@````4
M9UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9````L0`
M``"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``
M!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E12
M0P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ
M```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````````
M`````````````````````````````````````````````%A96B````````#S
M40`!`````1;,6%E:(`````````````````````!865H@````````;Z(``#CU
M```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D
M97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)
M14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````````
M````````````````````````````9&5S8P`````````N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M`````````````````````````````&1E<V,`````````+%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````
M``````````````````````````````!V:65W```````3I/X`%%\N`!#/%``#
M[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`````````
M`0````````````````````````*/`````G-I9R``````0U)4(&-U<G8`````
M```$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`
M8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0
M`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!
M60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#
M`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"
MX`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@
M`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%
M'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[
M!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L(
M'P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE
M"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+
M^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN
M#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0
MN1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C
M$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6
M;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1
M&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4=
M'AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$
M(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LD
MVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&
M*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78M
MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C
M,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`W
MG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC
M/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"
MM4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB1
M2-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/
M`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U
M5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<
MAES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.7
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MRHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)
MEC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?
MBY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DW
MJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBS
MKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*
MOH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S)
M.LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)
MU,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@
M-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[
M[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GX
MJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;
M`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``
M$0@`%0"C`P$1``(1`0,1`?_=``0`%?_$`:(````&`@,!``````````````<(
M!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$
M`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1
M)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1E
MH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::G
MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($
M!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!
MT4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#
MT^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8
M:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"
M$0,1`#\`V,>TNYNX_DU\@5ZEV%NS,[2VI)N_);1V_CL%DLABJ67'86IJDS.\
M=T2XR>AK,S>CQDU<M-*_B@A1(HD$Q>67C?[D>[7NO]XCWQ'M?R3S/=[7RRVZ
MRV5M%;RRPH8K=G$]]=M"T<D_Z<,EP(7;1'&J11J)2\LG2GDKV\]OO9KVJ//?
M-&QV]_O@L([J>2:..5A),JF*TMQ('2'OD2$R*-3N6D=O#THAZ-RY[K[X>;6P
M^V=IXJLW?O\`S5$TTN5W-EZG(YFLIX;039O<67J6J:NGQ\]:K"FH*18*9G60
M1K$%=O>3WN7[C^W_`-S'E?9>6>5MHEWKW&W"`N)+NX>29HT[&NKR=M<BQ/*"
M(;6`1Q.ZRB,1!'?K!/G+GKF#W!W2;<-V>*&SU$QVT"+%;PBIHJ1H`&8#!EDU
M2L`-;G%`HV[\W]]4^5A?=NUML9/!/*!5P[=AR>*R]/"Q`:6BER.7RE'4M`MV
M$,BQ^4^GS1@ZACORI_>)>XEMO5N_._)NT7?+C/\`JK8I<6]RBF@+1-/<W$4A
M05812*GB'M,\0.H`\VRT[6->K'\!G<5N?"8K<6$JDKL1FJ"FR6/JD!434M7$
MLL19&`>*50VET8!XW!5@""/?5[EGF/9N<.7MEYIY>O5N-CW"VCG@D%1JCD4,
MM0:%6`-'1@&1@58!@0$9!4D'B.JO_GW\T?D'U3W;\8_AK\-MB=7;O^3WRA_O
MUGZ'<7=M=N.FZIZLZXZXQT61W'NS<]!M2>@W!FZJL@-2*.*EJ-2/0N#!4O+#
M"\M<H\L[/N&U[YS+S+=SQ[%8:%*P!?%EDD-%12]54#%:C\7%0"0!>:N8]VL=
MRV;E[EVU@DWJ]UL&F+>%%'&*LS!2&-1JI0XT\&)`*/'7?\]0@$_)'^70"0"0
M.BN[&`/Y`8[V!8`_0V%_:CZSVL_Z,N\_\YX?^@.FOI?<K_HZ[3_SBE_S]!;N
MGY3?S-/A1W)\5,;\S7^(?=W0GRE^1>P?BXNY^A\#V/UWV3USV;VF];2[%R,V
M-WEN'+8'/;4DDQ]1-6+'$U3XZ=U62%S"LZ^WV'D?F;;=_DY;_>-KNUA9R76F
M=HY(I(HJ:Q5%#*^0%S2I&#FB&?>N<^7MQV--_6QN=KO;M+?5`LB21R25TL0Q
MTE``2V":`Y&*W9;JWMLS8F.&8WON[;&S<27\8RFZL]BMO8XR`:C&*W+U='3:
MP.;:KV]QC;VMS=OX=K;R2R>B*6/[`">I%GN;:U3Q+JX2./U9@H_:2!TFMI]U
M=-[]R1P^QNVNL]YY<(93BMI[\VMN+)",))(9#0X?*UE3H"1.;Z;64G\'V_<;
M9N5HGB76WSQ1^KQLH_:0!TS!N6W73^':W\$DGHKJQ_8"3T3[Y2_*;LOIGYE_
MRYN@MHT>T:C8_P`KMZ?(7;_9U3G,5DJW<5%0]6]34V]]M/M#(4F;QU#B:F;,
M2LM6U32URRP65%C;UD1;#L-EN?+7.>[W#2"ZV^*W:,*0%)EE*-K!4DXX4*T/
MKT0[UO=WM_,/*>U0*AMKYYQ(2"6'AQJRZ34`9)K4'RX><;K'Y6=F[P_F9?*#
MXA9:BVA'U5TY\?NENS]IUU%B<G#O2?<G8-95T^=AS>8ESE1BJW%1)`/MHHJ"
MGDC/ZI']VOM@L;;DC8^8HVD^ON;N:)P2-&F,=ND::@^I+$?+K5GOEW<<W[QL
M+JGT=O;1R*0#JJ]*U-:4R?(>7YG*W9W3TYL+)?P??/;/6>R\OH27^%;LWWM;
M;F2\<D<<J2?8YC*T=5H>*56!TV*L#]"/8;M]LW*[3Q+7;YY8_5(V8?M`(Z/[
MC<MNM'\.ZOX8Y/1W53^PD'I0[2WYL;?U%+DMB;SVIO7'0.D<]?M+<6(W'10R
M2!FC26JP]9601O(J$J"P)`-O;-Q:75HP2[MI(G/DZE3^P@=/6]U:W:E[6YCE
M0>:,&'[03UCW?V%L'KZDAK]^[XVALBAJ7,=/6;OW+A=M4D[J5#)#49FMHH97
M4NH(4DBX_K[W;V=W>,4M+625QY(K,?V*#UJXN[2T4/=W,<2GS=@H_F1U7I_,
M/^>%/T!\'^^_D-\8=^=+]E]C=44_7U318^3.8_L+;M)#NKM'96RZZ;/XG9NZ
M\9DEB_ANXIO"WW<`%1H)+`%&&')O*;;QS3M&S;[:7,%E<&0$Z3&QT1.XTET(
MXJ*X.*]!'F_FD;3RSNN[[)=6TUY!X=!J$BC5*B'4$8'@QID9IU8ZN<H:+;L&
MX,]D,=B:%,72Y#)9&OJH<?C:-9H(I)99ZJLF2&FIU>2UW>PXN?8+\)VF,,2%
MGU$``5)_(<>AB)56$32N%72"230#\SPZ#>A^1OQ[RE?#BL9WOTUD<I43?;4^
M-H>T-D5=?/4`E3!#1T^<DJ)9@01I52UQ]/:U]FWB-#))M5RL8%23$X'[=/2-
M-XVB1Q&FZ6S2$TH)4)_9JZ%BOR6.Q5%-DLID*+&XZF19*C(5]5!1T4".ZQH\
MU5421P1(\CJH+,`20/S[+T1Y&"1H6<\`!4_L'2]W2-2[N%0>9-!^WH/MU=V=
M,[$R;83>_;G6.S<RB)(V(W5OW:NWLFL<B)+'(U!E\K1U022.164Z+%6!'!'M
M9;[7N=W'XMKMT\L7JD;L/V@$=))]RVZU?PKK<((Y/1G53^PD'I:X#<>WMV8J
MFSNUL]AMRX2M!:CS&`RE#F<55J."U-D,=/4TDX!_*N?:::&:WD:*>)DE'$,"
M"/M!H>E,4T,Z"6"57C/`J00?S&.GGVUTYU__T-@CXNYBAVG\SZ2/<!%`]7O/
MLK::FJ`0TN>R<N=H*"DDU"Z5%5DD%(HX)EF"_FQXE_=PW6SY8^]M;1[X1`\N
M[;K9#7C1<S&XBC0UX,\H$`'$O(%\Z==1/>O;[G??N[S/M7ZJQ[?M]T=.=4$8
MA=V'JJQDRG^BA/ET:OYL[=RU'V1A-T31328/-;7HL315I!:"#)8>NRL]9BRP
M)$+&GR$=0@.GR&232#H<@3_WA7*N]V'NMR[SC/#(W+NX;/%;12\42XMIKEY;
M>N=)*3),@-/$+S:`?#<CF1;$:"OG7HFC,%!9C8#_`'W^W]X"LP4%F..E/5U/
MQZVWE]I]-[&PF=@EI<I%CJJNJ*.=62HH5S&4K\Q3T51&_KAJ*2FKT22,@&-U
M*D"WOZ"ONO<I[YR3["^W/+W,EN\.\I:22R1."'B%U<3721.IRKQQS*CH:%'#
M*14=%LI#2.1PKU4)\BHWH_\`A0+_`"]*VJM#29CXB?(?$8N5W`6LR>,I-^9/
M(4<"WN9J?'U,<K<<H?\`#C-79B&]H><57++N-N3\@3&`?V@CJ*MW!7W6Y2<_
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M@ED>=HIC&H+Q$,@C32*5HU>':>HCW!;_`''W!YIIRLF\1VD5M&B23QQ)"LL0
MD;LD!5_$:IK3MH:_$.F[Y(_$#M_L_J+>F$V9_P`)_P#H7XS]B4V#KLIUY\@N
MI?E[\6>L]Y]/[TQ<$M=MW?M'GMBX'9.3J:7;>4C2JGI):^&FJ8XRKLO#K?9>
M8MML=QM9KGW=N[ZTU`26\MG=2I,APT>F1G`+#`(4D'AU3=]DW2[VVZM[7VJM
MK*XTZDFBN[:,Q.N5DJ@2H4Y(+`$#B./1P^[ZCL6K^6G_``G:J>X)::H[9FQ_
MR$D[.J:+*8?-TE5V`?B+MK^^-539C;U15X#*05.X?N)%GHI9:24-JB9HRI(<
MVL62\O\`O(NV@C;P;?P@05(C^K;0"&HPHM,,`1YYZ$6X&\;?/:<[B0;\I/XA
M!!!D^FCUD%:J:M7*D@^6.A,Z:R5%AOYXG\P;,9*<4N.Q7PK^-.2R%24DD%/1
M4-9EJJJG,<*232"&")FTHK,;6`)X]H=R1Y?:[E"-!5VW.Y`'J2`!TMV]UC]Q
M^:)'-$7;X23\A0GJM+X>]:;%[/ZGJ>ZNCOY&S?-+K[N3?W9._P#$?)WYI?('
MXBU??/:\N7WQFXLKF]P8O>>SZROVWCX<O134])217B,4/F\M4\KU<XVYBO;J
MQW!=MW3W3_=E[;0QQFVLK>[$$0"+15*.`QH023FII10`H!FPVL5YM[7FW>V9
MW*RGFD<7%Y<6IFD)=@S,KH=.00`.-*U8DLRBPFU<ATI_-'_EFY/`?RYZ/^6;
MN?LW=_R)V-OJBZJ[!ZDW;U=W]UVO3E5F:?";ABZ8J<?@!GMG;E@6M^URF'@E
MU34M53U,[TP%&Q+.FY<B<[I)SD=[@ACMY$,L<J2P2>-0LOC`MI=<55SP92`&
M[E,4<UCSIR:XY2.SS2-<1L(Y(WBEC$8(5O"(4%#G2R#BK`DJ-)GOA%\8.@/F
MG\L_YI'=_P`M>J-D_(G?G7/S=WI\=>N8>X\%C^P-M]>=2]88+;W]U<+LW:&Y
MX<E@<`]2V0=ZFIAIQ)4NFH,#).92/FG?-VY9V#D3:^7[^2SM)MK2XD,+&-I)
MI2VMG=:,U*8!./R%#GEK9]LY@WOG;<M[LTNKE-P>W42@.J118151JJ..33/Y
MFJ/_`)W_`/+Q^$G5_P#+P[K[IZE^-G472_9W7=3UK-M[=O4.S,#UE75E-N+M
M;8NT\S@-QQ;0HL11[KP.3Q.9E'V=?'41QU"QSQ!)HU<*?:WG#F>_YSVS;=PW
MJXN;*82!EF=I0-,3NK*7+%&!494C%0<'I)[F\J\NV7)VXWMCM,%O<PM&5,2B
M/XI41@P2@8$,<,#FA&1T+_RSV!M/Y5?S6?A!\4._:'^^OQPVO\0NSOD:O3V:
MJJI>ONQNW*;<N/V5BYMZX"":FHMZ#:."@^[HZ6M^YAI]4X\8AJJI)R[E^[N-
MAY!YIW_:6\+>9-QCMO&`'B1PZ2YT-DIK8T)%"<9JJT,M[M8=ZYXY:V;<@7VJ
M*Q>X$1)"/+JT@L!35H`!4&M,^3,#8-DOY7'\MS+8RJQ%7\$?B8M%5TK4DGV/
M0O6V+K(XFC,0:CR>,V]1Y/'U,:F\<T$T<T;`,C*P!`/3GOG1'5QS5N%0:YGD
M(_,%B"/D01T+#R9RD=?_`"&[$,P()$,:MGCW!0P)]0:]:]6Z9LC@/Y(G\X[H
MD9W-[DZY^+/S7[F^/O24&ZLM6;FK]N=1[$[IZ8J]I;3&7R<U34Y''8*?*3_;
MZV;QH^A;(J*LQ0!)?=#VWW7PD2\O]KAN)]("AII()@[Z10`M05]>/KU$4K21
M^VWN#M@F=K2QW.6WAU$L5BCFAT+J-2=-30]7A]&_RI?Y>N(ZMV34;E^)W2G;
M&\<]M/"YK>_9W=&PMO\`;'9?8&Z\_BZ/);GW;N[>>_*//YO(9G<>8GEJYPLR
M4\4DI2".*(+&L6;KS[S?+N%V(-_N;>W61E2*%VBCC120J(D94!54`#%2!DDY
MZE#:^2^6(MNLUEV:">4HKL\RB61W859V9]1U,Q+&E`"30`8Z*Y\+^G^OOB=_
M.`^8?QU^/V!BZVZ)WK\2.EN_*OJ?!U%4FQ\'V9+O[/;-K<UM3!33S4FW(LCB
M=9F@I1'"S.%"K%%#'&>\R[C=\P>W7+F\;O+XVZQ;A-;B5@-;1>&'"LW%J'@3
MG\R22/E^PM=DY_W_`&O;(_"VZ:QCG,8)TB37HJH/PU!X#'Y``7S>XHZD[K__
MT=CKYFTOQTJNYLR-L9W?N$[-CJZ)MX'8VT\/NG:M7NLB$0PTZS[SV=E,=O9'
M\)K)*`U4+5-@R+7?<-[X\?>TMO86Y]VMU_J[O6]V?N(LL9OOW=907EF]YC2J
MAK^QFBW`'09WMC,AFH&07GCGKI']WF?W;A]O-O\`WSMFUW/)IC?Z7ZRYEMKE
M;;-2U+2[CDLR-0B6<1N(\JQMO"'5DVR(=P4_3U/%\G<CM7,8DXND>IKMWX7'
M[<S4::5%)2[NQ<.?W5MZ;<P-F6?'UD<AETJ(1-J;WGGLD5S![.B/[T-_L]UR
MZ;5#+)N4$-K*!0>&E]#]3>6K7E<I):SJ_B:52+QZL<(?<B3D>7F?<'Y#M)+>
MR\5@468W%J37+6LDD%M.(:X5)8F/$B31I'2-ZU_V3?\`O;1?W%_NY_>G[J+^
M$_QO^]MOXAYA]M_`_P"^O^XW^)>>W@^U_>U6\?X]P[[2_P#`&?UWL/\`6X_=
M7]<_&7Z;ZO\`>7]OJ_3^D_>WZ'CZZ>%]-^KJT^'Y=`)_J-)UUT_ZO3HY7O/;
MI/U1]_.B'PQ.)^,P[[?Y31_)<]C98?#V3X+QB;Y<)N@QX$;S?KJ*LE@V_+A%
M3^%')+7.DC-X11L)[GW*7MG_`%E\3?/W3]!^Y/!'UGUW^XFGNT>)3NU?'IIC
MCJQU&GN-_5S1LW[U^M_?/BGZ3Z+_`'*U=NOPZXI\&JN>&G/5=L>/^6)CC,.[
M_P#A2Z(?&GA%1US\+VJ!%H'B%0U1VDE0TX2VLR`2%KZ@&O[%Y?8*FMMR37Y2
M7E/R_2Z#(3>*"EQS=2GG'!7\_P!7J)L*#H.#Y9_$I?YA>4_G493*MW-MX_&J
M3Y[X'JW`?%./OW6G^CM*^'I/<FY)9]_'.>'^'--)'1@ZOXDIQWW)]WNCNYY>
MYA_J?'RRL?TS?4_0M(UU]/\`Z)3QE7]/3752I_@[]/3,`V@;_L/]:GYB9_J%
M^G^L55M?'_T.OALQUZJ:?P_Q]E>C0_/R+X]S?S`9T^/5;_,CQ_SV/4&`_P!-
ME3_+?Q?6.8QB=;"6D_N`/DI0]T9?!]>25S47B_A!^X6H%)]M]P"OV'LBY2.\
M#E`'>%V4\I_4-X`W$R`^)GQ/IC"&DI6NO%*ZM/X^COF8;.>;*;6V[#F?Z<>,
M;`(5\/&CZ@2%5K2FC/#3J_!T6[Y"TN^X.J=S-\[<]_/UR?Q;-!`.WX*C:7\O
MG![&78OWM+_'F[4JOCUO7<78[]>_:?\`%W6EA6?[$2\\FQQL[6IOX?ZK1<IK
MOE3X7??L^NAT^$)T6/Q*_!4TU4Z0;PLXLG_K!+S*VU=OB:4M573J%?$,3LVC
M^.@KIKU:'VO_`+);_LQ7\EK^`GM<1?8=P_[(V.HEV:>ECLS_`&6_;_E_TLMO
M9AOY=LCJO[/^[_\`!P:PUG_`W]OV![#^L_[G]S/%\"NJ'Z[Q=?C:_J&_LM'Z
M>KQ:^)KQ3X>A9=_U<_>OM]X/C4\.7Z+PM/@Z/!C_`+35WT\/3X>G/'5Y=+3K
MC_99?^'5?F<:,]Q?Z?/]E8Z1_P!,@W@O70^.HZN\V0_NV=G-2L=_'<QC\W\9
M&5`QWA_S/Y]I;S]^?U"Y;U?3?NGZ^;P='B?4>+^+77LT\-&GNKQZ56G[F_KG
MO^GQ_P!Z?21^+KT>!X=%TZ?Q5_BU8^+Y=4Q?%2CR\W5]/)_+DW%_/9Q_Q$.X
M=[#J.EVQLSX`9GJY,6-YYH9ANJZ_Y&;\P6^I=E/N3[LTHJZ9*Y6,@JRU8*HF
M2>8&07Q'.4/*IYAT)XI9[X2UT+I\46\;)KTTK0Z>&GMT]`+8%!LR>59N8AL?
MB/X8T6QC^,ZO",KJVC7JI45XZLUZ%/J>+KN+^8!\&$^5M?\`SH<A\D!O?LH_
M&NI^7.)^*N(Z'>8]79_^_P"IHNI,UG,=%"N$\)K6Q=0^;-7_``X3`4?/M#N!
MO3RAS2=@3EH;+X<7U(M#=&>GBKX>954_%73J&BFNG=TILQ8#FSET;TW,!W>L
MGT_U(A$%=/ZE`A;.FFJAK\-?+H2OD/%TU-\[/D,GP=K_`.:/COD??8Q^7-3_
M`"_L3T1FOCV-_#%_[]9.V:'Y.9K`=>-VRVV]/D;$5`B6,5'W*FL.0LBV@[F.
M5-G/-";$VR]_T@OS.MQX=>[PC;*TGA:OXQ7X:=NCI7N(VP\T[J.7FWD;MV?5
M?1B,V^NG;X@F*IXE/X33XJ]_B=%#^8\'7,'4&Y%_F@97^>YD^LVAQQV5-O7;
M_P`,<'UQ%OW^.X7^"ICZ?X_;FW#UQ4=FFA^\.,;?4L>(%)]X*93D_M#[$7+)
MOCN,']1H^55OJG7H:[:3P]+:JF=5D\*M-7@`O73J[-71!S2-O%A)_7*3F1K&
MG;5;=8]>I=.(V9/$IJT^*=.G73OT]6K?S2A\33N7XA#<[?,%/F@:G=0^);_`
M=,?)\LEVP<'C/]*;21Y^2+K"3K!<-]N<XNY&6G--]T*,B+^)'V`N1/ZP>!S%
MX'[N_JU1?J_KZ_2ZJGPOA_5\7571X>:Z=6='0UYU_<7C<O\`C_O#^L%3]-]%
M_N3IH/$K7]/P]/QZ\Z=>C'B=%$S5%\TDP=5)N?<O_"AFJVH*.1JVDV9LC^5C
M0;W?'?;R$QXS(;0[!R.](LO]M<*]/2O5>>Q">32/9_$W+1F400<H"XK@N^YF
M.M?,/&$I7U-*?+HKF7>Q"QFFYF,-,A$LQ)2GD5D+5^P5K\^A&R?_``V6?Y%_
M>/\`H\/R(7XA7G_T[':*X!OF&.V/]*FR?[^_W_7N)DP)[B_O?]C_`!;^(D47
M\,T_P_\`R3['VE3^O'^NGM?U?T?]8J?H:]7T?A>$_A^'X7=X.C5HTYU_'W:^
MK-_4S_6VW#Z;ZK]P:AX^G3]5XOBQZ_$\3'B:M.ORT?V?;HZV!MA?PW^XVS/X
M-]__``C^Z>W?X5_%?MOXI_#?X/1_8_Q+[/\`R/[_`.UT^;Q?M^2^GTV]Q%=Z
M_JKGQ*>)XC5I6E:FM*YI7A7-.I3M='TUOX=?#\-:5I6E!2M,5IQICJO'97^R
M_?\`#NO=_P#"3W5_LS7^R2]7_P![ADEV%_H!_P!$O^E++_W=.VFI6_TD'LH[
MB\OWHJA_"OL=/B/E]C"Y_>_^M[MGB?3?N/\`><FBFOQ_%\(:M5?T_#TTI3NK
KQQT%K?\`=/\`7F_\/ZC]]?N]=5='@^%X@TT_'KU>O;2ORZLZ]@?H8=?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X1"717AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`P-SHP-3HQ
M."`P,#HQ-#HU,P```````Z`!``,````!``$``*`"``0````!````9*`#``0`
M```!````B0`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```]A````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`B0!D`P$B``(1`0,1`?_=``0`
M!__$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]+KR<FRMMC<?VO`<)>.")4O6RO\`N/\`
M],*6%_0Z/^+9_P!2%G_6>EYZ1DY-=]V/;B4V6UFEY9+@TEOJ;?IMT1%7LQGB
M$>+B)TNO3_WK>];*_P"X_P#TPEZV5_W'_P"F%5Z:QF!TK[1=?;:TUB^U][S8
M1[`Y^USOS/;]%4_JMUC*Z@S)JS73?6YMK`6ED57-WU5[7-9N]%PLJWHUOILC
MBUB#*0,Q8^7_`+UUO6RO^X__`$PEZV5_W'_Z87.X'5^K6]=&*;7NI=E9%9;8
MRL5&FF?;1:R,AV2QSJ_:[\Q6^M]3RZ<]V+7>[$JIQOM!=76RRRPEYK(8R_V>
MECM;ZEVW](E6M4%HR`Q,N*6AX?T'7];*_P"X_P#TPEZV5_W'_P"F%E=5ZGDM
M^K^-FX5SO4O=C@6M:P.<VUS&N+:[IJ8Y[7_GJ]A5Y5G32Q^39]HL!_3/%1LK
M)X;MHW8VZM+I=!<"3+A$I;<7Z'5/ZV5_W'_Z82];*_[C_P#3"S_JZ[/NKONR
M\MV2&W6T-8YC&@>E8ZL/_1-9[GM:J_0\OJ.7G9#LC(L--5]];*R*16X,>ZMC
M&[/UO>QON]Z5;[:($[X=9^O;Y/Q=CULK_N/_`-,)>ME?]Q_^F%@]8ZGU'&R^
MI6TY@IKZ?33;5C/:PML<_P!3=47$>M^D]/8STWKI*W%];7D;2X`EI[2.$B*Z
M!,9<1($I>G^YWX?^Y:OVV[[3]F^SGU-GJ?3$1.Q)-_WM?^@W_HQ)+3LGU?O'
M>OT?^]?_T/3\+^AT?\6S_J0AY;G/<,44LO;:QQ>VQT-+06MVD;+-V[>B87]#
MH_XMG_4A1=_3Z_\`BG_]54DM_1'T1N9DOI.._$I=26[#6;"6[>-FWT?HI!F2
MVWUABTBW:&;Q8=VT&0S=Z/T%<21M7#X_DT!CV`M<,+'#FO-K3OU#W:/M'Z'^
M<?\`O)LK%=F!K<O!Q\@,,M%CM\'^3OI6+UJK.S\LOQOK%3@X[=&4UD`C]XV/
M%C=[MRS_`-D]5_\`GM'^?_ZF1T_>'XL!R58$"1_U/5ZRZBV^G[/=A464B(J<
M^6Z?1]AIV^U+&INQ*S5BX=%%9.XLK?M$G\[:VE<G^R>J_P#SVC_/_P#4RZ/I
M6<S&Q&T=0ZICY=K-!>'-87-_X0;W>_\`EI&JW!70G<M8F/\`6/`VZFY5+2VG
M%IK:XEQ#;"`7.,N=I3])R"S`;7D?::^G8K,B2[U6N`?+OI.W^AN]TK0KL98P
M65N#V.$M<TR"/(A20MEX0:\-OE<S(Q0ZPYMW3\:RZL;O5<X%XVB1M>ZC\U:3
M3N:'>(E#ROZ+=_4=^0J57\VS^J/R)=$`5(CPMJ_][7_H-_Z,22_[VO\`T&_]
M&))?P5_WS__1]/POZ'1_Q;/^I"B[^GU_\4__`*JI2POZ'1_Q;/\`J0HN_I]?
M_%/_`.JJ26_HCZ-A1>QMC'5O$M>"UP\0="I))+GC^J87U7Z5D"C(Z?>=PW,L
M826N'\D^I^:J?VGZF_\`E?D?>?\`TJN[(!Y$_%9_56]5:UC^F-K>>'UO`G^N
MUQ+4*:T^7JR!"NWMB1>4^T_4W_ROR/O/_I5+[3]3?_*_(^\_^E5M>I];O^XU
M'_1_\FEZGUN_[C4?]'_R:/#Y?@Q^U_5'_A/_`*$AZ/\`6'H>,YF#B49-3+7@
M-#@7-#G::>][F[EU"Q^FGZPORA]NJIJQP"7%H&XG\T-VN<MA*J;.$2$:/T]/
M!^"+*_HMW]1WY"I5?S;/ZH_(HY7]%N_J._(5*K^;9_5'Y$>B[],^35_[VO\`
MT&_]&))?][7_`*#?^C$DOX(_[Y__TO3\+^AT?\6S_J0HN_I]?_%/_P"JJ4L+
M^AT?\6S_`*D*+OZ?7_Q3_P#JJDEOZ(^C822227*223.<UH+G$-`Y)T"2F-U3
M+JG5/G:\02TD'^RYJQ3]6;>W4LF/ZW^U6\XY.0=N/FU8]8\#+C_:W*G]CZA_
MY;#[_P#S)$6M(B=_S=NFIM-3*FDD,``+B23'=SBIK)PJ\RBX.MZA7D5G1S''
M7^P=WTEK()%=$65_1;OZCOR%2J_FV?U1^11ROZ+=_4=^0J57\VS^J/R(]$?I
MGR:O_>U_Z#?^C$DO^]K_`-!O_1B27\$?]\__T_3\+^AT?\6S_J0HN_I]?_%/
M_P"JJ4L+^AT?\6S_`*D*+OZ?7_Q3_P#JJDEOZ(^C8225?+?EL:W[+6+'$^Z3
MQ_U*22:%I+;JZ6[K#'@.Y5#(R,+)CU6V$#AH,#[@4C;UD\T,_#_R:7J]8_[C
MU_A_Y-*CT(6&5]#_`(J'TND_Z.S[_P#S)+TND_Z.S[__`#)'%G6"0/0K$]S'
M_DE?8TAH#X+HU($"4O5^\@1!_1`\XTT\7I^"=MS:B(U;O,_VMLJ^DDEYL@B!
ML`/)%E?T6[^H[\A4JOYMG]4?D4<K^BW?U'?D*E5_-L_JC\B/1'Z9\FK_`-[7
M_H-_Z,22_P"]K_T&_P#1B27\$?\`?/\`_]3T_"_H='_%L_ZD*+OZ?7_Q3_\`
MJJE+"_H='_%L_P"I"B[^GU_\4_\`ZJI);^B/HV%&Q@L8YCI`<()!@_(A20[K
M/3K)#FM>0=F\PV?-)<Y?["RI_P"4+ML\:S'^>M6FIM-;:VDD-$2XDD_UG%8#
ML?K[G%W[5H;)F!$#R'M3?9>O_P#EM3^'_D4:'<,?N']T_@]&DL[IK\FFHUY^
M53>X&66-(!C]U_"OL>QXEC@X>(,H+P;#)))))*+*_HMW]1WY"I5?S;/ZH_(H
MY7]%N_J._(5*K^;9_5'Y$>BW],^35_[VO_0;_P!&))?][7_H-_Z,22_@C_OG
M_]7T_"_H='_%L_ZD*+OZ?7_Q3_\`JJE+"_H='_%L_P"I"B[^GU_\4_\`ZJI)
M;^B/HV%G=:Z?B9F+ORF6/&/+P*?I\>[:W\Y:*222`007@_7^I_[V7]P2]?ZG
M_O9?W!=7U;]HTU,?TS&IR'S%E=@@P?SF&6-67]L^M?\`Y4X_WC_THEQ2[_@U
M)1E$T:/EBG+_`+IR/7^I_P"]E_<%=Z;U[ZN=,+_L[\HML^DQ[06S^]&GN5K[
M9]:__*G'^\?^E$OMGUK_`/*G'^\?^E$N(]_P0#(&QI_U&?\`WSK=+ZW@=5:\
MXCSNK^E6\;7`?O;?W5?7.59GUL]1H'3,=DD`NW1`[_1>NC2;.*9D-;L=XG'_
M`-)%E?T6[^H[\A4JOYMG]4?D4<K^BW?U'?D*E5_-L_JC\B/1=^F?)J_][7_H
M-_Z,22_[VO\`T&_]&))?P1_WS__6]/POZ'1_Q;/^I"%?;73F5OL.UIK>)@D3
MNKTT1<+^AT?\6S_J0J'6NH96/;B8>(YE5V8Y_P"GL:7M8RIGK6N%32WU+/\`
M1L1`LK)$"`)\&[^T,/\`TGX'^Y+]H8?^D_`_W*IT'/=FXMCG9+,QU=A9ZM=;
MJM(#FMLJM_PON]ZK_5_K67U;?8]M+:F2',9ZF\.W%C)-C&TN^@[^;>E6_@@9
M+X=1Z]M.W^$Z?[0P_P#2?@?[DOVAA_Z3\#_<L3J_UJMZ;FY>,ZAI934QU%I)
M`=8[W&A_[KO3WOK_`*BT.O=5MZ7AU7UM8XV7,I)LW;0'S[_T0?9[8_-:EPG3
MQ1[H]6H]'S:+]2?B9^%;BC*?CN>/9=5N:YKA]%PV[5S/_-G._P#GER?NL_\`
M2JZW%NS+NGBX^D<BQI=7MWBLSK5N]1K;F_R_8JO1<_J6<Z]V570RJBVRC]$7
MEQ?6[8YWO:/T;D02`5LX1G*/%=D:5Q1_Z,FGT#!'2G7/RNJW=0=:`&BW?M:!
M^ZUQL]SEL_M##_TGX'^Y"P<ZS)R<ZES0T8EPJ:1,D%E=VYW_`&XJ_3.I=1ZA
M8,EE-3>FO=8QCB]WK?HW.K%CF;?3_2/9]#=[$C9U*Z!$0(Q/>M)2V/JZMG(S
ML5V/:UKY)8X`0>2/@K5>E;0?`?D6-UGKF5T_-92*ZZ\8L:XY-_J"MSB[8ZH6
MTLLKH=6WW_IUM`@B1J#W0.RZ)!E+6R-#I33_`.]K_P!!O_1B27_>U_Z#?^C$
MDOX*_P"^?__7])QLEM>-56^NT.8QK7#TW\@`?NH/4*<#J-3:\FJ^:W!]5C&6
ML>QP_/KL8T/8M))$;Z+#7#ZB.&NH<WI].#T^I]>.S()M>;+;+&VO>]Y@%[WV
M-=[O:@]/P,+I[P<=^:6-#@VE_JNK&X[G;:BW;]);"26NOXK?1Z=1_4H./F]-
MZ5G#(&33>_[4:C9[+!!I_FG5^SV<HW4*L3J%+*KAD-%;VVL=6RQC@]OT'![6
M>:TDDM=-U'@]6L?ZVGC_`-\T<1U.+2*0<FT`D[[FV6/U_EN:FQ!B8;;&TLNB
MZU]S]U=A]]AW/_,5]))<*]-$;>G3HT,<8N-;D75LOWY3Q9;-;R-P:VOV^SV^
MQC57HZ?TS'R_M5+,EIW.L;4!=Z37V?SMC:(]/<^5KI):^*WTZ:QW].GZ3D9^
M#T_/L+\@9>U[0RVIGK-K>T&=EM31M=])7QEU-`:*[0!H`*G_`/D%822-KHU9
MHB_TM'.];_*?K^G;Z?H;-WIO^EOW;?H_NI+122_@CZ_I=NK_`/_9_^T52%!H
M;W1O<VAO<"`S+C``.$))300E```````0`````````````````````#A"24T#
M[0``````$`!(`````0`!`$@````!``$X0DE-!"8```````X`````````````
M/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S````
M```)```````````!`#A"24T$"@```````0``.$))32<0```````*``$`````
M`````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`
M!@```````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"
M24T#^```````<```_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@`````_____________________________P/H```X0DE-!`````````(`
M`3A"24T$`@``````!``````X0DE-!`@``````!`````!```"0````D``````
M.$))300>```````$`````#A"24T$&@`````#/P````8``````````````(D`
M``!D````!0!L`&\`9P!O`#(````!``````````````````````````$`````
M`````````&0```")``````````````````````$`````````````````````
M````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0``````
M`%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````
M0G1O;6QO;F<```")`````%)G:'1L;VYG````9`````9S;&EC97-6;$QS````
M`4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG````````
M``=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG
M:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E
M`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4
M;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````B0``
M``!29VAT;&]N9P```&0````#=7)L5$585`````$```````!N=6QL5$585```
M``$```````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````
M#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````
M"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0`
M```)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L
M=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````
M3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``
M```````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG
M```````X0DE-!"@```````P````!/_`````````X0DE-!!0```````0````"
M.$))300,``````]]`````0```&0```")```!+```H(P```]A`!@``?_8_^``
M$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!
M_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"`")`&0#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`````````
M`P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$
M`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$
M`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#T
MNO)R;*VV-Q_:\!PEXX(E2];*_P"X_P#TPI87]#H_XMG_`%(6?]9Z7GI&3DUW
MW8]N)39;6:7EDN#26^IM^FW1$5>S&>(1XN(G2Z]/_>M[ULK_`+C_`/3"7K97
M_<?_`*857IK&8'2OM%U]MK36+[7WO-A'L#G[7._,]OT53^JW6,KJ#,FK-=-]
M;FVL!:615<W?57M<UF[T7"RK>C6^FR.+6(,I`S%CY?\`O76];*_[C_\`3"7K
M97_<?_IA<[@=7ZM;UT8IM>ZEV5D5EMC*Q4::9]M%K(R'9+'.K]KOS%;ZWU/+
MISW8M=[L2JG&^T%U=;+++"7FLAC+_9Z6.UOJ7;?TB5:U06C(#$RXI:'A_0=?
MULK_`+C_`/3"7K97_<?_`*865U7J>2WZOXV;A7.]2]V.!:UK`YS;7,:XMKNF
MICGM?^>KV%7E6=-+'Y-GVBP'],\5&RLGANVC=C;JTNET%P),N$2EMQ?H=4_K
M97_<?_IA+ULK_N/_`-,+/^KKL^ZN^[+RW9(;=;0UCF,:!Z5CJP_]$UGN>UJK
M]#R^HY>=D.R,BPTU7WULK(I%;@Q[JV,;L_6][&^[WI5OMH@3OAUGZ]OD_%V/
M6RO^X_\`TPEZV5_W'_Z86#UCJ?4<;+ZE;3F"FOI]--M6,]K"VQS_`%-U1<1Z
MWZ3T]C/3>NDK<7UM>1M+@"6GM(X2(KH$QEQ$@2EZ?[G?A_[EJ_;;OM/V;[.?
M4V>I],1$[$DW_>U_Z#?^C$DM.R?5^\=Z_1_[U__0]/POZ'1_Q;/^I"'EN<]P
MQ12R]MK'%[;'0TM!:W:1LLW;MZ)A?T.C_BV?]2%%W]/K_P"*?_U522W]$?1&
MYF2^DX[\2EU);L-9L);MXV;?1^BD&9+;?6&+2+=H9O%AW;09#-WH_05Q)&U<
M/C^30&/8"UPPL<.:\VM._4/=H^T?H?YQ_P"\FRL5V8&MR\''R`PRT6.WP?Y.
M^E8O6JL[/RR_&^L5.#CMT9360"/WC8\6-WNW+/\`V3U7_P">T?Y__J9'3]X?
MBP')5@0)'_4]7K+J+;Z?L]V%192(BISY;I]'V&G;[4L:F[$K-6+AT45D[BRM
M^T2?SMK:5R?[)ZK_`//:/\__`-3+H^E9S,;$;1U#JF/EVLT%X<UA<W_A!O=[
M_P"6D:K<%="=RUB8_P!8\#;J;E4M+:<6FMKB7$-L(!<XRYVE/TG(+,!M>1]I
MKZ=BLR)+O5:X!\N^D[?Z&[W2M"NQEC!96X/8X2US3((\B%)"V7A!KPV^5S,C
M%#K#FW=/QK+JQN]5S@7C:)&U[J/S5I-.YH=XB4/*_HMW]1WY"I5?S;/ZH_(E
MT0!4B/"VK_WM?^@W_HQ)+_O:_P#0;_T8DE_!7_?/_]'T_"_H='_%L_ZD*+OZ
M?7_Q3_\`JJE+"_H='_%L_P"I"B[^GU_\4_\`ZJI);^B/HV%%[&V,=6\2UX+7
M#Q!T*DDDN>/ZIA?5?I60*,CI]YW#<RQA):X?R3ZGYJI_:?J;_P"5^1]Y_P#2
MJ[L@'D3\5G]5;U5K6/Z8VMYX?6\"?Z[7$M0IK3Y>K($*[>V)%Y3[3]3?_*_(
M^\_^E4OM/U-_\K\C[S_Z56UZGUN_[C4?]'_R:7J?6[_N-1_T?_)H\/E^#'[7
M]4?^$_\`H2'H_P!8>AXSF8.)1DU,M>`T.!<T.=II[WN;N74+'Z:?K"_*'VZJ
MFK'`)<6@;B?S0W:YRV$JILX1(1H_3T\'X(LK^BW?U'?D*E5_-L_JC\BCE?T6
M[^H[\A4JOYMG]4?D1Z+OTSY-7_O:_P#0;_T8DE_WM?\`H-_Z,22_@C_OG__2
M]/POZ'1_Q;/^I"B[^GU_\4__`*JI2POZ'1_Q;/\`J0HN_I]?_%/_`.JJ26_H
MCZ-A))))<I)),YS6@N<0T#DG0)*8W5,NJ=4^=KQ!+20?[+FK%/U9M[=2R8_K
M?[5;SCDY!VX^;5CUCP,N/]K<J?V/J'_EL/O_`/,D1:TB)W_-VZ:FTU,J:20P
M``N)),=W.*FLG"KS*+@ZWJ%>16=',<=?[!W?26L@D5T197]%N_J._(5*K^;9
M_5'Y%'*_HMW]1WY"I5?S;/ZH_(CT1^F?)J_][7_H-_Z,22_[VO\`T&_]&))?
MP1_WS__3]/POZ'1_Q;/^I"B[^GU_\4__`*JI2POZ'1_Q;/\`J0HN_I]?_%/_
M`.JJ26_HCZ-A))5\M^6QK?LM8L<3[I/'_4I))H6DMNKI;NL,>`[E4,C(PLF/
M5;80.&@P/N!2-O63S0S\/_)I>KUC_N/7^'_DTJ/0A897T/\`BH?2Z3_H[/O_
M`/,DO2Z3_H[/O_\`,D<6=8)`]"L3W,?^25]C2&@/@NC4@0)2]7[R!$']$#SC
M33Q>GX)VW-J(C5N\S_:VRKZ227FR"(&P`\D65_1;OZCOR%2J_FV?U1^11ROZ
M+=_4=^0J57\VS^J/R(]$?IGR:O\`WM?^@W_HQ)+_`+VO_0;_`-&))?P1_P!\
M_P#_U/3\+^AT?\6S_J0HN_I]?_%/_P"JJ4L+^AT?\6S_`*D*+OZ?7_Q3_P#J
MJDEOZ(^C84;&"QCF.D!P@D&#\B%)#NL].LD.:UY!V;S#9\TESE_L+*G_`)0N
MVSQK,?YZU::FTUMK:20T1+B23_6<5@.Q^ON<7?M6ALF8$0/(>U-]EZ__`.6U
M/X?^11H=PQ^X?W3^#T:2SNFOR::C7GY5-[@998T@&/W7\*^Q['B6.#AX@R@O
M!L,DDDDDHLK^BW?U'?D*E5_-L_JC\BCE?T6[^H[\A4JOYMG]4?D1Z+?TSY-7
M_O:_]!O_`$8DE_WM?^@W_HQ)+^"/^^?_U?3\+^AT?\6S_J0HN_I]?_%/_P"J
MJ4L+^AT?\6S_`*D*+OZ?7_Q3_P#JJDEOZ(^C86=UKI^)F8N_*98\8\O`I^GQ
M[MK?SEHI))(!!!>#]?ZG_O9?W!+U_J?^]E_<%U?5OVC34Q_3,:G(?,65V"#!
M_.898U9?VSZU_P#E3C_>/_2B7%+O^#4E&431H^6*<O\`NG(]?ZG_`+V7]P5W
MIO7OJYTPO^SORBVSZ3'M!;/[T:>Y6OMGUK_\J<?[Q_Z42^V?6O\`\J<?[Q_Z
M42XCW_!`,@;&G_49_P#?.MTOK>!U5KSB/.ZOZ5;QM<!^]M_=5]<Y5F?6SU&@
M=,QV20"[=$#O]%ZZ-)LXIF0UNQWB<?\`TD65_1;OZCOR%2J_FV?U1^11ROZ+
M=_4=^0J57\VS^J/R(]%WZ9\FK_WM?^@W_HQ)+_O:_P#0;_T8DE_!'_?/_];T
M_"_H='_%L_ZD(5]M=.96^P[6FMXF"1.ZO31%POZ'1_Q;/^I"H=:ZAE8]N)AX
MCF579CG_`*>QI>UC*F>M:X5-+?4L_P!&Q$"RLD0(`GP;O[0P_P#2?@?[DOVA
MA_Z3\#_<JG0<]V;BV.=DLS'5V%GJUUNJT@.:VRJW_"^[WJO]7^M9?5M]CVTM
MJ9(<QGJ;P[<6,DV,;2[Z#OYMZ5;^"!DOAU'KVT[?X3I_M##_`-)^!_N2_:&'
M_I/P/]RQ.K_6JWIN;EXSJ&EE-3'46DD!UCO<:'_NN]/>^O\`J+0Z]U6WI>'5
M?6UCC9<RDFS=M`?/O_1!]GMC\UJ7"=/%'NCU:CT?-HOU)^)GX5N*,I^.YX]E
MU6YKFN'T7#;M7,_\V<[_`.>7)^ZS_P!*KK<6[,NZ>+CZ1R+&EU>W>*S.M6[U
M&MN;_+]BJ]%S^I9SKW95=#*J+;*/T1>7%];MCG>]H_1N1!(!6SA&<H\5V1I7
M%'_HR:?0,$=*=<_*ZK=U!UH`:+=^UH'[K7&SW.6S^T,/_2?@?[D+!SK,G)SJ
M7-#1B7"II$R065W;G?\`;BK],ZEU'J%@R64U-Z:]UC&.+W>M^C<ZL6.9M]/]
M(]GT-WL2-G4KH$1`C$]ZTE+8^KJV<C.Q78]K6ODEC@!!Y(^"M5Z5M!\!^18W
M6>N973\UE(KKKQBQKCDW^H*W.+MCJA;2RRNAU;??^G6T"")&H/=`[+HD&4M;
M(T.E-/\`[VO_`$&_]&))?][7_H-_Z,22_@K_`+Y__]?TG&R6UXU5;Z[0YC&M
M</3?R`!^Z@]0IP.HU-KR:KYK<'U6,9:Q['#\^NQC0]BTDD1OHL-</J(X:ZAS
M>GTX/3ZGUX[,@FUYLMLL;:][WF`7O?8UWN]J#T_`PNGO!QWYI8T.#:7^JZL;
MCN=MJ+=OTEL)):Z_BM]'IU']2@X^;TWI6<,@9--[_M1J-GLL$&G^:=7[/9RC
M=0JQ.H4LJN&0T5O;:QU;+&.#V_0<'M9YK222UTW4>#U:Q_K:>/\`WS1Q'4XM
M(I!R;0"3ON;98_7^6YJ;$&)AML;2RZ+K7W/W5V'WV'<_\Q7TDEPKTT1MZ=.C
M0QQBXUN1=6R_?E/%ELUO(W!K:_;[/;[&-5>CI_3,?+^U4LR6G<ZQM0%WI-?9
M_.V-HCT]SY6NDEKXK?3IK'?TZ?I.1GX/3\^POR!E[7M#+:F>LVM[09V6U-&U
MWTE?&74T!HKM`&@`J?\`^05A)(VNC5FB+_2T<[UO\I^OZ=OI^ALW>F_Z6_=M
M^C^ZDM%)+^"/K^EVZO\`_]D`.$))300A``````!3`````0$````/`$$`9`!O
M`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$@!!`&0`;P!B`&4`(`!0`&@`
M;P!T`&\`<P!H`&\`<``@`$,`4P````$`.$))300&```````'``@````!`0#_
MX1?Z:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G
M:6X])^^[OR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@H\>#IX
M;7!M971A('AM;&YS.G@])V%D;V)E.FYS.FUE=&$O)R!X.GAM<'1K/2=835`@
M=&]O;&MI="`S+C`M,C@L(&9R86UE=V]R:R`Q+C8G/@H\<F1F.E)$1B!X;6QN
M<SIR9&8])VAT='`Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A
M>"UN<R,G('AM;&YS.FE8/2=H='1P.B\O;G,N861O8F4N8V]M+VE8+S$N,"\G
M/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C,V-C%B.65E
M+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8B<*("!X;6QN<SIE>&EF/2=H
M='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R<^"B`@/&5X:68Z0V]L;W)3
M<&%C93XQ/"]E>&EF.D-O;&]R4W!A8V4^"B`@/&5X:68Z4&EX96Q81&EM96YS
M:6]N/C$P,#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z4&EX96Q9
M1&EM96YS:6]N/C$S-SPO97AI9CI0:7AE;%E$:6UE;G-I;VX^"B`\+W)D9CI$
M97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I
M9#HS-C8Q8CEE92TP-&8V+3$Q9&,M8C,Y-BTY9C$Y,6-F,S%B-V(G"B`@>&UL
M;G,Z<&1F/2=H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O)SX*(#PO<F1F
M.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U
M=6ED.C,V-C%B.65E+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8B<*("!X
M;6QN<SIP:&]T;W-H;W`])VAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\G/@H@(#QP:&]T;W-H;W`Z2&ES=&]R>3X\+W!H;W1O<VAO<#I(:7-T
M;W)Y/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70])W5U:60Z,S8V,6(Y964M,#1F-BTQ,61C+6(S.38M.68Q.3%C
M9C,Q8C=B)PH@('AM;&YS.G1I9F8])VAT='`Z+R]N<RYA9&]B92YC;VTO=&EF
M9B\Q+C`O)SX*("`\=&EF9CI/<FEE;G1A=&EO;CXQ/"]T:69F.D]R:65N=&%T
M:6]N/@H@(#QT:69F.EA297-O;'5T:6]N/C<R+S$\+W1I9F8Z6%)E<V]L=71I
M;VX^"B`@/'1I9F8Z65)E<V]L=71I;VX^-S(O,3PO=&EF9CI94F5S;VQU=&EO
M;CX*("`\=&EF9CI297-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5
M;FET/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70])W5U:60Z,S8V,6(Y964M,#1F-BTQ,61C+6(S.38M.68Q.3%C
M9C,Q8C=B)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+R<^"B`@/'AA<#I#<F5A=&5$871E/C(P,#<M,#4M,3A4,#`Z,30Z-3,M
M,#4Z,#`\+WAA<#I#<F5A=&5$871E/@H@(#QX87`Z36]D:69Y1&%T93XR,#`W
M+3`U+3$X5#`P.C$T.C4S+3`U.C`P/"]X87`Z36]D:69Y1&%T93X*("`\>&%P
M.DUE=&%D871A1&%T93XR,#`W+3`U+3$X5#`P.C$T.C4S+3`U.C`P/"]X87`Z
M365T861A=&%$871E/@H@(#QX87`Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S
M:&]P($-3(%=I;F1O=W,\+WAA<#I#<F5A=&]R5&]O;#X*(#PO<F1F.D1E<V-R
M:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2=U=6ED.C,V
M-C%B.65E+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8B<*("!X;6QN<SIX
M87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R<^"B`@/'AA
M<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C,V-C%B.65D
M+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S,6(W8CPO>&%P34TZ1&]C=6UE;G1)
M1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2=U=6ED.C,V-C%B.65E+3`T9C8M,3%D8RUB,SDV+3EF,3DQ8V8S
M,6(W8B<*("!X;6QN<SID8STG:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S
M+S$N,2\G/@H@(#QD8SIF;W)M870^:6UA9V4O:G!E9SPO9&,Z9F]R;6%T/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H\+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO
M`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S
M4D="``````````````````#VU@`!`````-,M2%`@(```````````````````
M````````````````````````````````````````````$6-P<G0```%0````
M,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8
M````%&=865H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0`
M``+$````B'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE
M87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(
M#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V
M+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````
M``````````````````````````````````````````````````!865H@````
M````\U$``0````$6S%A96B``````````````````````6%E:(````````&^B
M```X]0```Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0`
M`+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````
M```6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````
M`````````````````````````````````&1E<V,`````````+DE%0R`V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````
M````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@````````````````````````````!D97-C`````````"Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````
M```L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0``````````````````````````````````=FEE=P``````$Z3^`!1?+@`0
MSQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S````
M``````$````````````````````````"CP````)S:6<@`````$-25"!C=7)V
M````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`
M60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&
M`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!
M3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R
M`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"
MRP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'
M`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$
M_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99
M!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'
M^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ
M"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+
MR`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX
M#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0
M?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C
M$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6
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M)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE
M/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y"
M,$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%
M2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.
M;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;
M52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;
MY5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P
M8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJ
MGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+
M<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9Z
MI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T
M@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+
M_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3T
ME5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">
MKI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2
MJ,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNR
MPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5
MO8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(
M/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$
MT\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?
M*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KE
MZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOW
MBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D0```
M``'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`__``!$(`(D`9`,!$0`"$0$#$0'_W0`$``W_Q`&B````!@(#`0``````````
M```'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q``
M`@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q
M@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#
M=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:
MI*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"
M`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S
M";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$
MA:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7
MY_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,
M`P$``A$#$0`_`-XG;_9/8FYL!@]R8OJ)CC-PX?&9S'?<[]P$-3]CEJ*"OI/N
M(5I)5BG^WJ%UJ&8*UP"?K[,_I=O&&W.C?\TV_P`_0"M^9>;;NW@N[7D?5;2H
MKH3>P@E6`921HP2"*CRX=._][NT_^?0Q_P#HPL#_`/4'OWTNW?\`1T_ZI-_G
MZ>_?O.G_`$P@_P"RZ'_H#KW][NT_^?0Q_P#HPL#_`/4'OWTNW?\`1T_ZI-_G
MZ]^_>=/^F$'_`&70_P#0'7O[W=I_\^AC_P#1A8'_`.H/?OI=N_Z.G_5)O\_7
MOW[SI_TP@_[+H?\`H#KW][NT_P#GT,?_`*,+`_\`U![]]+MW_1T_ZI-_GZ]^
M_>=/^F$'_9=#_P!`=>_O=VG_`,^AC_\`1A8'_P"H/?OI=N_Z.G_5)O\`/U[]
M^\Z?],(/^RZ'_H#KW][NT_\`GT,?_HPL#_\`4'OWTNW?]'3_`*I-_GZ]^_>=
M/^F$'_9=#_T!U[^]W:?_`#Z&/_T86!_^H/?OI=N_Z.G_`%2;_/U[]^\Z?],(
M/^RZ'_H#KW][NT_^?0Q_^C"P/_U![]]+MW_1T_ZI-_GZ]^_>=/\`IA!_V70_
M]`=>_O=VG_SZ&/\`]&%@?_J#W[Z7;O\`HZ?]4F_S]>_?O.G_`$P@_P"RZ'_H
M#KW][NT_^?0Q_P#HPL#_`/4'OWTNW?\`1T_ZI-_GZ]^_>=/^F$'_`&70_P#0
M'7O[W=I_\^AC_P#1A8'_`.H/?OI=N_Z.G_5)O\_7OW[SI_TP@_[+H?\`H#I&
M?Z:=Z?Z1/]&'^B.H_O/_`'(_O_\`\?Q@/X;_``/^\']V_%]Y]KK_`(C]]Z_'
MX]'BYUZO3[<^@L?"\?\`>?Z>K3_9MQI7A7TZ1_ULYJ_>'[K_`*C_`..^#XM/
MK(::-6BNK1QU>7IFO7__T-Z_IG_F3_5/_B-MC?\`O,8OW9_[23_3'_#T3<N?
M\J]L/_/%!_U:7HH/\S;:.5K?B)W;VIMKM3N/JS=_1'3O;W9NT*_J7L;,[`CR
M6X\'L3)9'%1[P3#E3N7"45;C8Y%I)F$6HL?J00;;),%O[:W:&)HY945M:*V-
M5"!J!I6N2,X&>@;[J[7)=<I[QO%OO&X6MYMUC<S1BVG>$.XBU+XH2AD"E.U2
M0!J;UPM_CCB,'\=OBK%V1O+M/MC?F)GZXH.\-\[I[E["RG8F9P\2=;X;,;DI
M\/ELX5J,;MV"+%RU,5$&\44\TK+;784W#7<[E);QPH&$K1J%55KWD+4``5\J
M_MZ4\FK#R]R+:[S?;K=SQ26*7DKW,S3,A-NCR!6>K!,$A:FA)IQZ+7_*S^7O
M9WR0Q/=&UN\LK45W96U\]M#M';M/6[-K=AU&-Z:[QVS#N79&U5PV2P&W*S+3
M=;YK&Y;;]9E5AFAKJBB\BSRAPWM9OVV16'T3P`>&R%6HP:KH:$U!(&H4:F*>
M@X=!?V;YXW3FRUWVUWV=WW.&9)DUQF(BWN$#(@4QQEA"X>/Q`&#4!$CUKT6W
MHGY:_+'=OSII.IJK?F]<ML;,?*;Y9;&GQ&_-A],X7IFKZ5Z)&2I?X9U=OO;B
MT';N:[LVOF<GB#4T%?$]-/CC4U!UQ022A9=V%@FW2S+#'K2WA-59S)KD"DF1
M350O&A'J!QZ"W+G.?.-WSW!M,FY7,EI-O.XPZ9HK9;4VMHS#3;R(JSM<IVU5
MJ@J"QJ*GHP7S8^3?:VS>^,UU-MCM;<?16S^OOC5%W]/F=@=9[`[0[/[5R^2W
M[E=FU^/VY@.SJB+;U1L?IW%XB/,[GAH0,M/2U\8CF@5072;9M\$UE]4T`EE:
M8I1F*HO;45*YUN31*T6HS7H3\_<U;S9\RG8[3>)MOLH=N%UJ@AAGN)V:5HSI
M6XI']/;*OB7&@^*584(X]/ORJ^2_8M!\`.D>]^C>Q-Q+N;M+<7Q2I<?OK$;1
MZ^Q&Y=T8#N+=NS<%FJ[&[0['ER6P-M9C<F)W#)-2TV2JEI,=4R1K+4!(W<L;
M=;P-O+6MU;@0@S55BQ"Z$=@*J0QTE0*CXAPX]*><^9]WA]L]EW_8-TF^ON)+
M`"54A225;B6*-SHE$D,9D#D@,=,9(JP`)Z-/TQ@.TMS_`!QJL1F^\.Q3V=NB
MFSAC[$W3@^B*SL;K/(Y((:#$U>&ZMH<GTQDLKM2,JR!$KJ:;6#*TP-RCNS"E
M\6CA3Z<%2%76%8"E?C.L!J&N014TICH8[!;;O=\K-;W6]W:[O*'!ED%H\]NS
M<%I`AMF,8H5[6!!!:O0'_P`O+*=\[WP/:>^^Y/D5NKN"GPW<?=G3.#VUF=B=
M7;3QN(I^H>V-R;,H-TQ56P]J[?R-7FL_B</&:V*HDEI4E),$<0N"8\P0VEM/
M:PVEHL8,*.2"QJ74&G<3@>5/7->@?[07_,>]V&][KO\`S)/>>'N-U:)&\<"*
MJVTS(L@,4:,7=1W`DK_"!T$7P>[6^0O<7>7;N3[([E[*FV%L3O+Y'=?[7VA7
MX7XS4?6&[,5L;L+<6RMLX'$S[>AC^0B[FVKC*1*RIFR$%+153TS%9)T/NVZ1
M65M;Q106T?BF.,EAXNM241B22?#.HDBBUI\CTB]O-SYIWK?-TN=UWV].VP7]
M[$B,+'P)5BFDB2-0B"[#QJ%?4U`VDY(K4.?F#\E_D+U7VW\UMU[*^26,V%MK
MXI=+=$=H;)Z2W-LOK?,[7[=S^\Z;?E3GMD9#+9'&T?9$=9O";:--C\><3DDF
MIZVN#(DA*Q%;8;?8S6&T>)9%Y;B256<,P*A:48"NFBUJ:C@.B+FSG#FG;N;/
M<0V?-"VUALUE8SPV[Q0M'.\P8O"Q*B;5*5"H4>H9A0'AU=9@,E49C`X3+U>/
MGQ-5E<1C<E4XJJ-ZK&5%=1PU4V/J3I2\]%)*8WX'J4\#V$6%&8`X!_U>O60U
MO*T]O!,\11W16*GBI(!*GAD<#@=%X_[G._\`+8?_`)JOM=_RS/\`F_\`\^=!
MK_G>/^I3_P!K'7__T=Z_IG_F3_5/_B-MC?\`O,8OW9_[23_3'_#T3<N?\J]L
M/_/%!_U:7I+]L9*NSE;!U%!UGL[LS%;YV9NROW5AM^[@_A&V*O;>.K=NX.MP
MU=CSM#>$.=BRYW,%E@FAC@\,;!B^K3[>MF".9O':-XRI!45-3JH1D4IIX])-
M\F:ZE7E_]TPW<%U;2M(LKZ8S&IC1D(\.35K\7((`H#6M:=,&2P_8V9V;/UWE
M^@>E<GL*JP:;8J=F5_9==5[7J-N14J4,>!GP<_33XV7#K11K"*9HS#X@%TZ>
M/;ZR1)-]2M[*)]6K5IS7C6NOCTFFLKZXVQMEGY8L'V@Q"(PF<F,Q@!0FCZ;3
MI``&FE*"G7*EQ79-#N8[TH^@NEJ3=[;:H]FMN>F[,KH<\VTL?6S9*@VRV5CZ
M:6M;`T.0J))X:0N8(I9&=5#,2=%H#'X)O)?"U:J:<:J4K37QICJ\=MN,5Y^\
M8N6K%;_P!#X@G(?PE8LL>KZ:N@,20O`$DCI.TW7F?HJS&9"D^,'Q\IJ_"[US
M?9&(KH-\M%68OL'<U-4T>X][8^I3I59J3=6?I*V:*MKXV6IJHYG65V#L"X;@
M%64[A-I*!#V\47(4]_`4%!Y4Z0Q[&8I89H^3ML6:.Z>Y1A+0K<2@K),I^FQ(
MX)#L,L":UKU%[1ZNR7=])B*#N3XI_'#M6BV_6OD<%3=A;OBW?#AZZ41K-4XQ
M,]TC7"AEJ$B59#'I\BJ`UP`/=89DMBQM[^9"1G2M*_L?J^\;/)S#'!%OO)^V
M7D<35032^)I)XE=5J:5H*TXTS7IUW=LK=>_]G0]=[Y^-'0&[]@4XQBP;(W)O
MILSM*%,+H_@Z1;=K^E)\1''BC$AIE$(6`HI0+I%MPS);R^/!?3+-GN"T.>.=
M=<^?5MQVNXW?;TVG<^4]NGVQ2I$3S%HQH^"B&VTC3^'&/+KOKC9F[NGL#-M7
MJCXV="];;9J,I59N?;VQM_S;6PLN7K8J:"LR;XS"]+T=$:ZKAHXEDET:W$:W
M)L/>KB:.Z?Q;F^E>2E*LM33TR_5]IVZ[V&U-ELO*NWVMH7+%(IBBEB`"Q"VP
M%2``3QH!Z=/.UL?V;LBAK,9LWH;IK:V.R.9R^XZ^AV_V=D,325N?W!6R9+.Y
MJJIZ'IN"*?*YG(S//53L#+/,[.[,Q)]UE>&=@\UY*[!0`2M<`4`^/@!@=.[?
M:[CM4,EOMG+5A!`\KR,L<Y4&21BSN0+8`L[$LQXDFIZ#+!]"8S;._5[4VY\-
M?BU@NS5R65S'^D+$;AHL=O5LMG8*RFS>2?<])T;%F9*[,09&=*J5IB\ZS/K+
M:C[42WK3P"VFW.=K<4[2M1V\,:_*F/3HGL^5;3;]S_?-CR+M,6[:W?QDDTR:
MI*ZVU"VK5]3:CQ-37CUAW_UA1UVX:OO+?7P^^,^Z]^[0QJYZ'?>9W%C\YOFD
MBVC1S5V..+W#E>D)<E!5XR.%OLK3QB"0@JR<M[O:S/((MNAW2=89'"Z:47N(
M&0'X5X^O2;?=KM+9MPYQW/D3:Y]RM(&F,ID#3$0(64*S6WQ`+1"3VFF1QZ.E
MCZQ<A04->B-&E=1TU8L;$%HUJ84F5&(X+*'L;>RF1=#NA/`D?LZD2UG%U:VU
MT%($D:M3TU`&GY5Z+;_W.=_Y;#_\U7VL_P"69_S?_P"?.@Y_SO'_`%*?^UCK
M_]+>OZ9_YD_U3_XC;8W_`+S&+]V?^TD_TQ_P]$W+G_*O;#_SQ0?]6EZ;<A_S
M/?:?_B).P_\`WL>L/>U_LYOM3_!)TS-_RM.W?]*^X_ZO6O0M^Z='_7%W2-&D
MD941%9W=V"HB*"69F)`55`N2>`/?NO$@`DG'5!/S-VOWA\A>V\AG>J_YS/4/
MQCZSPP3&[7ZRZ^RN#Q^2I'AIX(,M7;RW5C>RL5D-SYBKR<,K*DBQTU'$5CBB
M#"220]L=VY7MK=8KS;Q-<?B8NO&IX"N`.'KZ]8V<Z1\T\P;U<W.S^]>S[=M*
MFD4,=PJ,J@`$R,DH+N6!)J2%P%"YJ4;_`&5'Y4_]]$./_P#0[;_[<7M7^_>3
M?^C)'_O2?Y^@C_5OGK_V8G;O^RP_];^O'XH?*@@C_H(AH.1;C?C@\_T([BN#
M[]^_>3?^C)'_`+TG^?KW]6^>?_9B=N_[+#_UOZN=^*?>.#ZMZDQ&P_DC\[?C
MAWWO;;;?84/:6*W-M;9V:W'@HHT%$V\\;/O',4E=N:D(,<M?3M"*R,*\L0G\
MDDH?W"^VB:<RV!\.(\59E(!_HT\OD?/AC`G+D[F.+;=I2QYM]P-CO;Z,@+-%
M<1JSI0?VH>0U<&O<M*K355JLQ_L%GL'NC#X[<.VLQB]P8',4L5=B<UA:^ERF
M)R=%,-45709"BEGI*NGD'Z7C=E/]?:?T^S_#P_;U)%M<VU[!%=6=PDMK(*JZ
M,&1AZJRD@CY@D=.WOW3_`$A.TO\`F678W_AB;N_]Y_(>UFW?\E"P_P":R?\`
M'AT&N<_^5/YL_P"E9=?]6'Z4&VO^/<V__P!J3%?^X$'MFX_MY_\`3G_">C3:
M/^23MG_//'_QQ>B^?]SG?^6P_P#S5?:G_EF?\W_^?.B7_G>/^I3_`-K'7__3
MWK^F?^9/]4_^(VV-_P"\QB_=G_M)/],?\/1-RY_RKVP_\\4'_5I>FW(?\SWV
MG_XB3L/_`-['K#WM?[.;[4_P2=,S?\K3MW_2ON/^KUKT+?NG1_TV9K#XS<6&
MRVW\U215^'SN,K\/EJ&:YAK<9DZ66BKZ2725;Q5-+.Z-8@V;WH@,"I%0>F+F
MV@O+:XL[F,/;2HR.IX,K`JP/R()'6NG\H>F_Y7_Q&W[2=?\`8_Q"[WKTR6'I
M<OMS=6U,[N'*;3W!1%5CK(,;D:GL>AG^_P`-5?LU4$L4<L9*.`T<B.Q/<Q[;
M:LJOMA:HK50Q'_'N/6)'.W*OLAR!N$.W[YR)NQ25-4<L3.\4@%-05C<J=2$@
M,K*&%0152"2V?Z2?Y.7_`'B)\D/_`#X9G_[:7M-XNT_]&I_]Y;_H+H%_O/[M
M_P#TQ&]_\;_[:NO?Z2?Y.7_>(GR0_P#/AF?_`+:7OWB[3_T:G_WEO^@NO?O/
M[M__`$Q&]_\`&_\`MJZ]_I)_DY?]XB?)#_SX9G_[:7OWB[3_`-&I_P#>6_Z"
MZ]^\_NW_`/3$;W_QO_MJZ/I\0OYA?PCZPKML="=,=5?)+9>WM];TH,=A*#<E
M%7[NP.%W%N6K@QT`H8*O>FXLGA<=D\E.C5"4<7A65VF9`3(Y,(-QMSX-LEO(
MD8PM5-!4\*DD@5./(?+J5O;SW5]KMEFLN4^6=KWFVMKNY54$RM)&DDA"BE9I
M6C5F(U!%TU)8@5)ZO>]F763G2$[2_P"99=C?^&)N[_WG\A[6;=_R4+#_`)K)
M_P`>'0:YS_Y4_FS_`*5EU_U8?I0;:_X]S;__`&I,5_[@0>V;C^WG_P!.?\)Z
M--H_Y).V?\\\?_'%Z+Y_W.=_Y;#_`/-5]J?^69_S?_Y\Z)?^=X_ZE/\`VL=?
M_]3>OZ9_YD_U3_XC;8W_`+S&+]V?^TD_TQ_P]$W+G_*O;#_SQ0?]6EZ;<A_S
M/?:?_B).P_\`WL>L/>U_LYOM3_!)TS-_RM.W?]*^X_ZO6O0M^Z='_7O?NO=1
MYZ2EJ@HJJ:GJ0A)03PQS!"UM17R*VDFPO;WL,R_"Q'5'CCDIXD:M3U`/^'HG
MWRFQORIQ5#M_-_%;%=9[AF$S8_=&S-X8#%I6-'+Y):;<&&SE;F,-1A*<CPU%
M)*2S!DDC8V=2HMQ'+*1<WLT:4P5TD5^=58Y^70/YHM^8HHX)^68+=S6CQM&A
M/R92Q48X,"?0CSZ)A_>#^;A_SY?H_P#ZD[,_^SOVN^EV[_H]W'[%_P"M?0-\
M7W._Z,MK_O$/_6SKW]X/YN'_`#Y?H_\`ZD[,_P#L[]^^EV[_`*/=Q^Q?^M?7
MO%]SO^C+:_[Q#_ULZ'CXX3_S!LQVACO]F"V/T_LWK&@H,C692JP=#A9]PY/(
M_;M#A\?AFP^XLRU*Z5TBSSRS(B"&(JI+L![8N(K.*,F'<9IG.-+!0OVFB@_8
M*]'W+@YXFW.,[Y96T.W("6(1-3&A"JI5FIG))I@4XGJR#V7]2/TA.TO^99=C
M?^&)N[_WG\A[6;=_R4+#_FLG_'AT&N<_^5/YL_Z5EU_U8?I0;:_X]S;_`/VI
M,5_[@0>V;C^WG_TY_P`)Z--H_P"23MG_`#SQ_P#'%Z+Y_P!SG?\`EL/_`,U7
MVI_Y9G_-_P#Y\Z)?^=X_ZE/_`&L=?__5WK^F?^9/]4_^(VV-_P"\QB_=G_M)
M/],?\/1-RY_RKVP_\\4'_5I>FW(?\SWVG_XB3L/_`-['K#WM?[.;[4_P2=,S
M?\K3MW_2ON/^KUKT+?NG1_U[W[KW7O?NO=>]^Z]TF]X;5Q>]]L9O:6:?)18O
M/X^;'U<^&RN0P>6IDE`T56,S&*J*7(XVOII562*:*161U!Y%P;(Y1U=:5!\Q
M4?L/3%S;I=036TI81NI!*L585\PRD$'T(/59DO\`+-W*SR^'YK?):*%I)/"K
M[BJI98H6<F-&F_C"+++'&0"^A=1%](^GLV&ZQ^>W0_L_V.H^/(-Y4Z><]R`\
MN\G_`)^ZLRV;M>AV3M3;VT<;4Y.MH=NXFBQ-/6YK)5F7R]<M'`D35N4RF0FJ
M*ROKZMU,DLLCLS.Q/TX]E#'4S-3))/IQ^0Q^SJ0+2W6TMH+9'9EC0+5B68T'
M%F)))/$DGI2^]=*.D)VE_P`RR[&_\,3=W_O/Y#VLV[_DH6'_`#63_CPZ#7.?
M_*G\V?\`2LNO^K#]*#;7_'N;?_[4F*_]P(/;-Q_;S_Z<_P"$]&FT?\DG;/\`
MGGC_`..+T7S_`+G._P#+8?\`YJOM3_RS/^;_`/SYT2_\[Q_U*?\`M8Z__];>
MOZ9_YD_U3_XC;8W_`+S&+]V?^TD_TQ_P]$W+G_*O;#_SQ0?]6EZ;<A_S/?:?
M_B).P_\`WL>L/>U_LYOM3_!)TS-_RM.W?]*^X_ZO6O0M^Z='_7O?NO=>]^Z]
MU$KZ^AQ=)/7Y.MI,=0TR>2IK:ZHAI*2G2X77-43O'#$NH@78@7/O:JS$*H)8
M^0ZI++%#&TLTBI$HJ68@`?:3@?GT3+O.?L7L6>+'=:_*#JSJ;;-.\4QEQE73
M5F[<G.B@L*W-G-10T5$LE],%-$C,/\Y(X](>2"8$EK=R/32?\W1=^]=K+ZCO
M%MI'`"6/T\^[/RX#[>BZ_P"B#O\`_P"]AN(_\_4?_P!??;OAR?\`*&W^\G_-
MU;][;3_T=K;_`)RQ_P#070M]+[?[@Z_WG25^Z_F)L'M3;>0:&@RNU]PUL,]4
M\<DH$51MZN7-M+C\PLCV4%9(I@=#I?2RM202L586\BT!\C0_;CR]>M?O3:VD
M0KN]O7A02QFM>&-7&O"F?+SZL']L=&?2$[2_YEEV-_X8F[O_`'G\A[6;=_R4
M+#_FLG_'AT&N<_\`E3^;/^E9=?\`5A^E!MK_`(]S;_\`VI,5_P"X$'MFX_MY
M_P#3G_">C3:/^23MG_//'_QQ>B^?]SG?^6P__-5]J?\`EF?\W_\`GSHE_P"=
MX_ZE/_:QU__7WK^F?^9/]4_^(VV-_P"\QB_=G_M)/],?\/1-RY_RKVP_\\4'
M_5I>FW(?\SWVG_XB3L/_`-['K#WM?[.;[4_P2=,S?\K3MW_2ON/^KUKT+?NG
M1_U[W[KW27W7O+;NRL<V3W#D(Z2(ZA3TZ@RUM;*HOX:*D2\M1(>+V&E;W8@<
M^V9[B&V3Q)GHO\S]@\^D]S=06D9EN)-*?M)^0`R3T4OL'?W2G:!I4WAC>Q:Z
MBHP#3XJFK7Q^*68$G[J2@H\S%!45=FL))`[*.%M[16_,\-JQ:%9`Q\]`)_*O
M#H';M<<N[XD<>YVMS)$O!:NJU]2JN`3Z$@T\N@Q_NU\3_P#GB]^?^?"H_P#K
MW[5_UTD_WY+_`+PO1#^X>0/^C)+^V3_K9U[^[7Q/_P">+WY_Y\*C_P"O?OW]
M=)/]^2_[PO7OW#R!_P!&27]LG_6SH?>LN@>CJT8W>V)V#F*803BHQ$>[:NHJ
M8YVB*/!DDQDM?5P21I(+PM*O+#6H_2WLQ3>;V\M]1D=8V\B`I(_+-#_,?+H1
M;7R;RFC6^XVVR:9%.I/$+'(X-I9F'S%1\QY'HUOM-T->D)VE_P`RR[&_\,3=
MW_O/Y#VLV[_DH6'_`#63_CPZ#7.?_*G\V?\`2LNO^K#]*#;7_'N;?_[4F*_]
MP(/;-Q_;S_Z<_P"$]&FT?\DG;/\`GGC_`..+T7S_`+G._P#+8?\`YJOM3_RS
M/^;_`/SYT2_\[Q_U*?\`M8Z__]#>OZ9_YD_U3_XC;8W_`+S&+]V?^TD_TQ_P
M]$W+G_*O;#_SQ0?]6EZ;<A_S/?:?_B).P_\`WL>L/>U_LYOM3_!)TS-_RM.W
M?]*^X_ZO6O0M^Z='_01=N9OMO#8_$_Z)MIXC<]?5550F5DRU;%3QXRFBCC>!
MXJ:6OQHJFJG+*2)?V]/Z3>X4VJ6K.?JY61`,4%23_.G1#OT_,,$$']7K"&><
MMW>(^D*M,4%5U5./BQZ'R`&7=?S'F8--U5L65E!"M+)02,H)N0"^[20"?:[P
MME_Y2I?]Y_Z%Z"_U_N;_`-&#;_\`G)_UUZQ_WE^87_/I=@_[?'?_`&6>_>#L
MG_*5+_O/_0O7OK_<W_HP;?\`\Y/^NO6:FS_S`J*B"!NK>NJ1)IHXGJJHT?VU
M,DCA6J)_!N>><PPJ=3!$=R!P">/>C%LH!(N)2?2G']J]7CO?<MY(T?9-N1"0
M"QD)"CS)`E)-.-`"3Y=&^Q.,FBQE#'FEQ-;EEIHQD:J@QJT5%-5Z;S-24LTM
M5+!3ZS9`TCMI')O[*FT%FT`A?*N3_DZ'T*RB&,7#*T^D:BH*J3YT!+$#T!)/
MSZ>@`````````+``<``#@`#WKIWKOW[KW2$[2_YEEV-_X8F[O_>?R'M9MW_)
M0L/^:R?\>'0:YS_Y4_FS_I677_5A^E!MK_CW-O\`_:DQ7_N!![9N/[>?_3G_
M``GHTVC_`)).V?\`//'_`,<7HOG_`'.=_P"6P_\`S5?:G_EF?\W_`/GSHE_Y
MWC_J4_\`:QU__]'>OZ9_YD_U3_XC;8W_`+S&+]V?^TD_TQ_P]$W+G_*O;#_S
MQ0?]6EZ;<A_S/?:?_B).P_\`WL>L/>U_LYOM3_!)TS-_RM.W?]*^X_ZO6O0M
M^Z='_31G\+1[CPN4P-?)70T>6HIZ&HFQE?5XK(PQU"%#-0Y*@F@K:&KA)U1R
MQ.KHP!!]^ZHZ:T9-1%?,&A'S!ZKT?X*=FFK9D^8/<*T!JF9(349=JQ:(S$K"
M:H[M\3U2T_I\OBTE_5HMZ?;RR@`!HP3U[2VF@?OIQIY^M,?LZL`VEMB@V;MW
M$[:QM3EJVDQ-*E,E=G<K79S,USB[35F3RN1FGJZVLJ969W9FL";*%4*H9Q5B
M!2IK^WKT:>&@4N6/F3Q)\S_L#`X#'2B]^ZOU[W[KW7O?NO=>]^Z]TA.TO^99
M=C?^&)N[_P!Y_(>UFW?\E"P_YK)_QX=!KG/_`)4_FS_I677_`%8?I0;:_P"/
M<V__`-J3%?\`N!![9N/[>?\`TY_PGHTVC_DD[9_SSQ_\<7HOG_<YW_EL/_S5
M?:G_`)9G_-__`)\Z)?\`G>/^I3_VL=?_TMZ_IG_F3_5/_B-MC?\`O,8OW9_[
M23_3'_#T3<N?\J]L/_/%!_U:7IMR'_,]]I_^(D[#_P#>QZP][7^SF^U/\$G3
M,W_*T[=_TK[C_J]:]"W[IT?])7>6?&WL#7U,&5VKB\S-25<.WFWEF!A<#49G
M[>1Z*&OJT66J^T$JAI1`CR^,'2+\C1>-"IE?2E>./Y5\^DUW<+;PNYEC20@A
M?$;2I:F`3QIZT!-.JE\CU[\]<CD:_(#^8#T;C175E35KCL7)C(,9CUJ)GE6B
MQ\,V`J)XJ*E5@D0>21]"C4S-<DW7<]B557Z8&@XEEJ?MSU%<^W\XSS2S?U\M
M$U,3I5@%6ODHH:`<!DGU)/4/_1A\]O\`O8=TW_YU8C_[&O>_WKL7_**O^]+_
M`-!=-?NKG'_PH-M_O8_Z!Z.W\;,YV7LK:V1V]\B.^^F>S\G!7?<;>W?MS/4>
M.S$M#4:WJ,9N&CFI\;CZ@T4UOMJB$*[1MHD4E`[%UW=[;(X>U8(#Q!*T_+/0
MUY?N;VSM3;;YOEE<.OPR*]'-220X-`:8`(IC!'GT;'%YG$9RF-;A,KC<Q1B5
MX#5XNNI<A3":,*9(3/22S1"5`X)6]Q<7^OM.KJXU(P(^6>A1%-#.FN"572M*
MJ017[1TY>[=.]>]^Z]TA.TO^99=C?^&)N[_WG\A[6;=_R4+#_FLG_'AT&N<_
M^5/YL_Z5EU_U8?I0;:_X]S;_`/VI,5_[@0>V;C^WG_TY_P`)Z--H_P"23MG_
M`#SQ_P#'%Z+Y_P!SG?\`EL/_`,U7VI_Y9G_-_P#Y\Z)?^=X_ZE/_`&L=?__3
MWK^F?^9/]4_^(VV-_P"\QB_=G_M)/],?\/1-RY_RKVP_\\4'_5I>FW(?\SWV
MG_XB3L/_`-['K#WM?[.;[4_P2=,S?\K3MW_2ON/^KUKT+?NG1_T3KYI]`]1]
MU=8KG.V<#V-GZ'J@9;>&/I.J6AFWM/`]"L&:HL5BJJ.:FS)FHX5E-.%^X<TX
M$)+'0ZNSNY;1V:*AJ*$&I!],#-?3[>@ASGLFV;MM3W&Y17#+:!I0(`&E("]R
MJI!UD@86E20`N<'7U_OK_)^_YV7S`_V.%PX/^L0:$$$?T/(][_K=%ZQ_\XY/
M\W6,G]=_9/\`Z.F\?\X!_P!`==_WU_D_?\[/Y?\`_GFPW_U#[]_6^'^*/_G'
M)_FZ]_7?V3_Z.N\?\X1_T!U[^^O\G[_G9_+_`/\`/-AO_J'W[^M\/\4?_..3
M_-U[^N_LG_T==X_YPC_H#HT'QL^>7\N3XKU>XGZSW+\K)\5NB&`9;;6Z-M4.
M7V\V0IF3[?-TM!`V/:CS"4ZF!ID<"6$A9%;1&41W?,-I>!1(R!AYA)*_9\/#
MH3<N^\?M1RR\_P!#N^[-#(,H\%4KCN`"@AJ8J#D<:T%+>_B[\U^@_E]1;CFZ
M@W!DGRVU)X5SFU=TXL[>W32T-2%^SS<>)EJ*@UF#JY28EJ87D1)D,<FABH9N
M&6*XC\6"0,E:'!!!^8(!%?+%#FG`]35R5[C\J<_I>'EV^9Y[<C7'(ICD`/!]
M!R4)QJ%0"*&AIT;/VYT.ND)VE_S++L;_`,,3=W_O/Y#VLV[_`)*%A_S63_CP
MZ#7.?_*G\V?]*RZ_ZL/TH-M?\>YM_P#[4F*_]P(/;-Q_;S_Z<_X3T:;1_P`D
MG;/^>>/_`(XO1?/^YSO_`"V'_P":K[4_\LS_`)O_`//G1+_SO'_4I_[6.O_4
MWK^F?^9/]4_^(VV-_P"\QB_=G_M)/],?\/1-RY_RKVP_\\4'_5I>FW(?\SWV
MG_XB3L/_`-['K#WM?[.;[4_P2=,S?\K3MW_2ON/^KUKT+?NG1_U[W[KW1-/E
M:/D+LO;&!S_Q6Z1Z;[8S9S$E'NW:6]J6/$9/^&U<0:CS>W\BF7P.,E%%5HR5
MD%1)Y'297B)T.K:DFN44>""[5`H6T_SR,=1YSP.:-MLK>\Y+Y7V_<;GQ*2Q2
MT1])X.C5530_&K9(-5.""1+_`$N_S6?^]?GQZ_\`/WAO_MB^V?J=T_Y1%_YS
MC_H'J,?ZQ>]7_A'MK_YRQ_\`6WKW^EW^:S_WK\^/7_G[PW_VQ??OJ=T_Y1%_
MYSC_`*!Z]_6+WJ_\(]M?_.6/_K;U[_2[_-9_[U^?'K_S]X;_`.V+[]]3NG_*
M(O\`SG'_`$#U[^L7O5_X1[:_^<L?_6WI^VQW!_-@&?Q4$/P9^/6VHZZNH\?7
M9M]TTN/@Q^-J:N`5U35U6,WW75RTM/"ID814]0Y*#3$[64Z\7<'91):(%KQ,
MP-/G0*2?RZ5V',?O:+N!%]J=L@#N%9_'50JDC425D+4`R:*QQ@$XZN875I76
M%#Z1K"DLH:WJ"L54LH/T)`O_`$]J.LAOMZ0W:7_,LNQO_#$W=_[S^0]K-N_Y
M*%A_S63_`(\.@USG_P`J?S9_TK+K_JP_2@VU_P`>YM__`+4F*_\`<"#VS<?V
M\_\`IS_A/1IM'_))VS_GGC_XXO1?/^YSO_+8?_FJ^U/_`"S/^;__`#YT2_\`
M.\?]2G_M8Z__U=Z_IG_F3_5/_B-MC?\`O,8OW9_[23_3'_#T3<N?\J]L/_/%
M!_U:7I&;XW3@]E]Q[,SFYJN7%XBHZTW_`(F+(M09&JI#DI=T]<5D5"\U#25*
M15,M+22R(KZ2Z1L1?2;7C1W28(A)JG`5_C]/MZ+=TOK7;>8=LNKZ3P[8V5P@
M8AB-1EMB%J`<D`D`\0#Z'I[_`-/G4?\`SV,'_GJSW_UJ]^\"?_?#_P"\G_-T
MI_K9R]_T<U_WE_\`H'KW^GSJ/_GL8/\`SU9[_P"M7OW@3_[X?_>3_FZ]_6SE
M[_HYK_O+_P#0/7O]/G4?_/8P?^>K/?\`UJ]^\"?_`'P_^\G_`#=>_K9R]_T<
MU_WE_P#H'KW^GSJ/_GL8/_/5GO\`ZU>_>!/_`+X?_>3_`)NO?ULY>_Z.:_[R
M_P#T#T!OR2RG5/R#Z7WQU11=Z;SZFS.YL9IV[V5UM5[TVWN_9>XJ.5*S#9S'
MUN'BQE164]-6PJ*JB>98:VE:2%R`^I5%H'M[F&:6P,L:G*LA((X'B#GT-,&A
MZ#_-.X;#S'L=_M,/,LEG<R+^G-"94>-QE6JFDE:X9=0U*2*@T(H\'\L[O"PU
M?SNODT387(Q';`%_S8'M,D"_L4_O;9?^F27_`'E?^M?6/G^M[S7_`.%UN/\`
M>;W_`+:>K#_@+TC#\0J_L?-=M_/SN+Y7Y7>U-@<9A*?L=-^+M[9>-Q$E;55<
MN+PN9S.[@^:S%76*):M9(;4\"1Z#RWLFW:XM[TP?0[+],JUKI7+$TXT5<"F.
M/$]2A[<;>O)[;G/S#[C3[M<3A50/X_AQJM22%D>4ZV)H6!4:0!0]63?Z?.H_
M^>Q@_P#/5GO_`*U>R?P)_P#?#_[R?\W4I_ULY>_Z.:_[R_\`T#TC^Q.[^KLG
MU_OG&X_=*U=?D-G;FH:*D@P^X))ZJLJ\+6P4U-!&F)+R33S2*JJ`2S$`<^U5
MA'*E]9.\3!!*A)(-``PJ3CAT0\U<Q[+><K\R6=K>B2ZEL+A$4*Y+,T+JJ@:<
MDD@`>9/0\[>C>+;^#BE1HY8\/C(Y(W4H\;I10*Z.K`,K*PL0>0?:6<@SS$'&
ML_X>ACM:-'MFW1NI#K!&"#@@A!4$>HZ+S_W.=_Y;#_\`-5]JO^69_P`W_P#G
MSHC_`.=X_P"I3_VL=?_6WK^F?^9/]4_^(VV-_P"\QB_=G_M)/],?\/1-RY_R
MKVP_\\4'_5I>BI?-+Y`]F];[H^/?1_365VELWL#Y$9_LGR]I;YVUD=[8'K;8
M'3>P:KL/?V9QVQL7E,'4[UWK78](*;$XYJR&%V>6636L.AC;:[&.Y2[NID9X
MH='8I"EB[:5&H_"*\30]`[W`YKW'8[GEO8]IGAM[[<WN#]1+&TJ016L)GF81
M*RF20H*1K6A."#4=._P0[VR7?'5N[\IEN\MB=_Y79_8^=V=)OK8W4>^NEXHJ
M2#&8;,8G$;PV-OFHGK,;OJEQ^7CFR$5(XI(TGA51JU,S>[6@L[B-1:M"&C#:
M6=7]<AE_"?*N?/I5[=<QS<R;1?3S;Y#N$D-V\0ECMIK;M`4JLD4U")0#WA>U
M:A:D@DA#_+]^:';?S'DS^X<]C>EL)M';D6;H<WM[:</<J[]P.?@W9EL!MZ*N
MR6\=GXCKS.8[)4.W*VHJ'PV3R!IG:&-B"6]J=WVRVV^*V,1E,D@4U8H5H4#&
MFDZJ@L!W*M<]!_VRY]W_`)YEO;B\BV^/;X=:E8ENQ,KB5HTJ98Q;NK"-V/A2
MR%:J#0D]!!\M_P":9NCXN]T_(/JVNZNV_787K[K#KO</4^]\GE<M28C>/:N[
M/'EZ_J;=$M/%)'A\Q6[+I,EE,,\1_P`N&-GAL9%"LIL-ABO;6RN!,VMV;6HI
M4(*C4,<`0`:^O1;S=[LWW*^_\R;/)ML/TUO!";>5BP5[B18W\"2C#N>,R-'I
M`_LZ5):@-W\\?E+N;XF=1;&[!VUB]G9*NW=W+UYU96U&]TWE+MW`T.]_XK'4
M;CJ*/8.)W!N_(_PJ2@5A345%53S*Q"H3S[+]HL(MPN)HI2^E(RW:5!-"!2KD
M+Y^9'0M]R.<+[DS8]LW*QBMVGN+Z&W)F$S1H)5<ER(%>4Z2HPB.Q!PIZ&#K/
M=O<>^.@,?O:9.IJOM'=.UJS<.SOX*W8N.ZOK!EH):[9$V67=>W\3V+C*.IH)
MJ9LC'+CHZR!S(J174#VFF6RCO3&OC?2*U&KHUXPU*$J<UIFAZ.MKO>9K_E5+
M\KMYY@FA+Q:3<+;'5F(OXD:W"@J5,@,8934`=`;\+^^/DCWU6=KY'MS:G2&V
M=I=;=F]G=*Q'K?/;\RVX<EO[JS=R;;S&4EAW1A<;CHMHY2".66E(<UBMH$B*
M";*MTMMOM3%':23-*51CK"@:70.*:36HJ`?+T/1![?<R<V\RG=[C?K/;HK&V
MNI[4?3O,SF:WE,4A(D4+X34)0@ZOXE'0N=&]WY[M3LSY3;'R^%Q&+H.@^X<-
MUK@:W'2ULE7GZ#*=6;#[$DR>72J9H:>LBJ-Z&E"0^@I3ASR^E6KVQ6TM]MG5
MR?'B+$>A#%?V4`_GT9<J\U76_P"^<\[5<6T:1;5?I`C+JJZM"DNIZXJ"U,4'
M0,_&;Y'_`")^2F>H>T,+UGU-A?B9N+=':NU-N9>KWSN:7O-8.MMR[AV70;RR
MVV1ME-GQX[>&YMLU")BDK?O,=2R1S2S2-JA#U]9V%FCP&XD.XH%U#2/#JP!*
M@UKV@\:4)X=%O*G-'-?-%S%NL6T64?)LLTZ(QFD^K"PL\8D>/1X?ZDB$:`^I
M%(+$D$$.?F+\X^T/C7W3MK9,.R^OMH]45NU-L;AJ>[N[(NVZ'K3<N=S6\:O`
M9SK^A[`ZWV-O#:G5^<VG@J:+)25FZG@I*W[V&*(*`\P=V_:[>\M7E,KM<U("
M)H+```U*,RLP)/X`:4/19SQ[@[ORKOUK8)8VD.SM"C&YNOJ4B=VDTM&LT,$L
M,1C6C,9V4=PX#)L_AEBGBBGAECFAFC26*:%UDBEBD4/'+$Z%E>.12"I!((/L
MBZEM65U5T8%"*@C((/`@^8Z++_W.=_Y;#_\`-5]K_P#EF?\`-_\`Y\Z"W_.\
M?]2G_M8Z_]?=MZU[(QVW>N>O]OY?:G:M-E<'LC:F'RE,O4/9DXILCC<#045;
M3B>GVM+3S^"IA9=<;/&UKJQ!!+LD;^))0`C4?QIZ_P"FZ!^R;S!:;-M%K<6-
M^L\=K$K#Z.Z-&6-0PJ(J8((P2/0]!WW_`+.Z)^2VVL%MWLW8_=_W&T-RT>\]
MB;PV?L'N[8_8&P-W4$%124^X]E;UVQ@,;GL!DFH:R:GF\4WAJ:>5HYDD0V]J
M;.ZO+&1G@"T9:,I:,JP/$,"V1_/T/1=S/:\M<VV,=CN^W[E^FX>.2.VO(IHI
M`*!XI$B#*P_,'%0:#KW0&T.DOC7MC<FV^M]K_("HFWMO#*]@[ZW7OC9O>>_M
M[[WWSFJ3'X_);JW1NC=>"R>1R65GH,32P`W2)(J=%5`!SJ]N;J_D629$`5=*
MA3&JJN310&P,GKW+%MR]RE836.UVNZMXLK2RR307LTTLK`!I9)'B)9VH*G`K
MY=!M\?\`HKIGXUY:BK.NMP?-6HV]BZ+<5%BNN-WMWWNKJ_%+N?*/FLE48O8N
M2VN<)CZM,G/++!)"B&`S2!;*Y'M^\OY[U`LEC;J]%&M2@>BB@&HR'R`KZTZ(
MN5N6]BY2NHI]NW/F66U02!;>9+M[93*VIF$(ME4-J)(/D6;&>L/='QP^*OR`
MB[EA[/Z[[QSB=Y5O3V3W@8^NNVJ27'93HJ:KFZ]R>T)HMG^7;%?1&OJ$J9:=
MM=5%42(YT.5/K;<+^U-H8E3]$.%JR?Z)QKWBM/+T^?3^^\O<I<PC??WA:;K7
M<)+9Y"MK<@HUJ"L9C)MSIJI*O75J5F`I4]";\@=J=2_)':6V=H;ZH/DAA*;9
MV^MM]D;:SG7FRNXMC[KQ&\=I)6K@,O0;CP^TDR-)-0/D)'`B9`7L3<"WMFRN
M;BQDD=((W#H4(<H00:$U&L>@Z,N:K79.;;&SL;T[S;BWN4GCDM[>ZBE62,,$
M8/\`3L1343BAK3/2PZER>TNHMG0;,HJWY/[\@@R&2R(W%VOM/NCL+>,SY.I:
MI>EJMS9S:TF1J:&C+:*:)V(AB`1>`/;,Y>:5Y1;QQ@_A1D"C%,#6>/$YXD]+
M]BN;#8MNCVY9]ZNPK,WB7,%W-,=1K1G,`J!P44P,=0^I(>J>E,?O7&[)VOW8
ME-O_`+/WWV[N(Y?J[M7)RR;R[&R[9S<\])))M!/M,=/D79X:=1HA!TKQ8"US
M+<731O)&FI8U3#)D(`H)[^-`!B@QPZ;V$[+R[#N$%A;[FT=S>37+:[2Y-))V
MUR!:0+1-52`:D5.3UUUY#U9UENSM[>>V=M]WG,]W[VH>P-\?Q+J[M.NHWW%C
M]JX+9=-)B*5MG1KBZ1=O;:HH3"A96:'6?4S$WN+BZN8K2&55T0H56C)P)+9[
M\Y/[.F]FBV'8]QYAW.RM=S-SN=PLTVJUN2NM46,:`(!0:5&"6-?/RZ!O8W07
MQKZW[;?M[9NV?D[A:Q-T[SWWB^O:6@^1L?3>W]]=B4]53;ZW=@>JH\>FT,?E
MMT+D*EZE/MVHUGJI9HH(Y7+^WY-QOI;7Z5XXBI55+?I:RJTTJ6U5HM!2E#ZD
M]%%AR_REMF^?OVSMMZ202R2K"(]P^FCEF!$LJ0",(&D#$,""GFJ*<]9N]>CN
M@OD5N"MS/8]/\MSBL]MS&[.WOL#:Y^26T^L^Q-I8NNKLA3;=WQL7!XZDP68Q
MTTV3J4J=,<,U7!.\,[R160>M-PO+*/1#!"6!)5F\)F4F@JI+?+SJ!Q`KU?F+
M9>6^9[P76XMORQ-&L<L,27\4$\:DL$EC6,`C4Q)*Z6:M&8KCHUU)VMM2@I::
MAHMI=HTM'1T\-)24M/TQV?%!34U/&L,$$,2;2"1Q0Q(%50````/9<4E8DE02
M?Z:?]!=#)-^V^)$CCL;Y8U```L[J@`P`/T>`'0)_WM_YR;_T@_W-[4_NG_H$
M_NE_%/\`1)V3_P`?)_I%_BW\*^T_NO\`>>7^%_O^3Q^#1QKU^GVKS^[_``L>
M)XU::DX:>/Q>N.B+]YQ_UJ_>/T%]]'^[O#U?27/Q^-JTT\*M=.:TI3SKCK__
MT-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
/O?NO=>]^Z]U[W[KW7__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
